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ABSTRACT 
 
Breast cancer is a leading cause of cancer death among women in Western and Asian countries. 
Previous studies showed that Asian and African-American patients more often had poor tumor 
prognostic factors than Caucasian patients. There are however only few reports on tumor prognostic 
factors and survival in Vietnamese breast cancer patients. The aim of this study was to investigate 
prognostic/predictive factors in Vietnamese operable breast cancer which were compared with those 
in Swedish breast cancer patients and to estimate survival. Primary breast cancer tissues were 
collected randomly for analysis of hormone receptors, HER2 status and cell proliferation. Clinical 
information, pathology report and treatment protocols were obtained from the files in the National 
Cancer Hospital, Vietnam.  
 
The hormone receptor content in tumors from Vietnam was analyzed by immunohistochemistry 
(IHC) using an automated slide stainer (Bench MarkXT, Ventana).  Tumors with ≥10% stained 
nuclei were considered as receptor positive. Tumors from Sweden were analysed with an enzyme 
immunoassay (EIA) with a cut-off point of ≥0.10 fmol/µg DNA as positive. We found that 
differences of ER/PgR positivity between Vietnamese and Swedish breast cancer patients. The 
ER(+) rate was higher in premenopausal but lower in postmenopausal Vietnamese patients as 
compared to Swedish patients (71.1% vs. 58.4%, 44.7% vs. 71.6%, respectively). The PgR(+) 
tumors were found in 57.8% of pre- and 24.7% of postmenopausal Vietnamese patients. The 
corresponding figure for Swedish patients was 72.9% and 65.6%, respectively. 
 
We used IHC and silver in situ hybridization (SISH) technique to assess the HER2 status for 
Vietnamese and compared to Swedish series with tumors analyzed by IHC and FISH. It was found 
that tumors from Vietnamese patients with strong, intermediate and low levels of HER2 protein 
expression were 39%, 11% and 50%, respectively. The concordance between IHC and SISH was 
87%. Postmenopausal women were amplified in 55% as compared to 36% in premenopausal 
women. HER2 gene amplification occurred more often in ER(-), PgR(-) tumors and in ductal 
carcinomas. HER2 gene amplified rate was present in 41% of Vietnamese breast cancers and 13% in 
a series of Swedish breast cancers.  
 
We chose the samples from age-matched patients treated in Stockholm, Sweden. Cell proliferation 
in the two series was stained by anti-Ki67 antigen with an automated procedure. Ki67 index was 
calculated by counting stained cell nuclei in a total of 400 cells in intermediate area. No difference 
in distribution and mean of Ki67 indices was seen between the two series, 27.7% (± 17.1%) vs. 
26.9% (±23.1%) or with respect to age, tumor size and lymph node status. Swedish patients with 
poor prognosticators had significantly higher Ki67 indices than Vietnamese patients, 52.8% vs. 
31.9% in ER(-), 39.6% vs. 30.7% in PgR(-) and 40.1% vs. 28.3% in HER2-amplified tumors.  
 
We estimated survival by using the life-table method. The Cox model was used to determine the 
relationship between survival and prognostic factors and treatment. The disease-free survival rate, 
overall survival rate and cancer-specific survival rate in Vietnamese patients was 75.8%, 80.6%, and 
86.4%, respectively at 5 years; 62.3%, 68.1%, 78.9%, respectively at 9 years. Women with poor 
prognostic factors had worse survival. Postmenopausal women had significantly lower survival as 
compared to premenopausal women as analyzed by univariate analysis (HR=0.6, 95% CI: 0.38-0.95, 
p=0.029), however, not by multivariate analysis (HR=0.67, 95% CI: 0.41-1.08, p=0.1). 
Premenopausal women had more benefit than postmenopausal patients from either endocrine 
treatment or chemotherapy. 
This thesis suggests that Vietnamese breast cancers have different tumor cell characteristics to 
those reported for Caucasian patients in general.  
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1 INTRODUCTION 
 
1.1 EPIDEMIOLOGY OF BREAST CANCER  
1.1.1 Incidence  
Breast cancer is one of the most common cancer among women in both developed and 
developing regions [1]. There are reports that the incidence varies among ethnicities 
and is low in Asian and African women, but higher in Caucasian women [2]. The 
incidence of breast cancer in women living in Hanoi, Vietnam (17.5/100,000) is much 
lower than reported for Vietnamese (36.6/100,000) and Caucasian women living in the 
US (98.7/100,000) [3]. Another  report on breast cancer incidence for Vietnamese 
women living in the United States found an incidence rate of 55.5/100,000 and this was 
lowest among Asian and much lower than non-Hispanic White women [4]. 
The incidence in Sweden was 145.2/100,000 in 2009 (www.socialstyrelsen.se). So far, 
all published data have suggested that Vietnamese women have a considerably lower 
incidence of breast cancer than Swedish women. A most recent study has shown that 
immigrant Vietnamese in Sweden had half the incidence of breast cancer compared 
with native Swedish [5]. This difference in incidence has been attributed to lifestyle and 
genetic factors [2]. Breast cancer incidence has been reported to have increased 
gradually in Asian populations in recent years [2]. There are no data on the incidence of 
cancer nationwide in Vietnam, but in a recent report of cancers from different regions 
of Vietnam it was shown that the incidence for all cancers increased continuously over 
time and that breast cancer was the most common cancer in females, 24.55/100,000 [6, 
7]. This increasing incidence of breast cancer is probably due to changes in risk factors 
such as childbearing, exogenous hormone exposure and reduced physical activity [2]. It 
seems likely that breast cancer will become a big burden for healthcare in many 
developing countries. 
 
1.1.2 Breast cancer mortality 
Breast cancer is still the major cause of cancer death, although mammographic 
screening has resulted in reduced mortality by as much as 30% [2, 8, 9]. The mortality 
rates in European countries declined by 6.9% between 2002 and 2006, from 17.9 to 
16.7/100,000 [10]. Breast cancer survival has improved markedly in UK, Denmark as 
compared to Canada, Norway and Sweden [11-13]. Breast cancer mortality after 
implementation of mammography screening in Sweden decreased 11% for women 
 2 
between 40 and 79 years [14]. This is also likely to have resulted from more advanced 
treatment [15]. Multidisciplinary management and adjuvant therapy should also be 
accounted for the increased survival [8].  
 
 
Fig. 1: Incidence and mortality in different regions 
worldwide. Estimated ASR per 100,000 [16] 
 
 
Variation in breast cancer survival was seen in different subpopulations [9, 17] or 
ethnicities [4, 17]. The mortality is higher in Caucasian, as compared to African-
American [18], which can result from various tumor cell characteristics which 
influence the outcome of treatment [19-21]. Socioeconomic status is also defined as an 
additional factor that influences breast cancer outcome [19, 22]. In recent years, several 
studies have shown difference in cancer mortality among Asian women. Interestingly, 
Vietnamese breast cancer patients had the lowest mortality rate among Asian women. 
In addition, it is also of interest that Vietnamese women living in the US, but born 
outside of the country had a risk of mortality close to four times as high as USA-born 
Vietnamese, while US-born Vietnamese women, who had a substantially lower risk of 
mortality (HR=0.3; 95% CI=0.1, 0.9) as compared with other ethnicities [17]. As 
mentioned above, although breast cancer is the most common cancer in Vietnamese 
women, breast cancer death has been reported to be 5.69% of all cancers in women 
nationwide [23]. Different biomarker frequencies in various populations may partly 
explain the variety of treatment outcome [19]. 
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1.2 PROGNOSTIC AND PREDICTIVE FACTORS  
Breast cancer treatment has been more individualized over the last decades due to the 
discovery of prognostic and predictive biomarkers. Prognostic and predictive factors 
are often related to various tumor cell characteristics while tumor size and lymph node 
status more likely reflect the duration of disease [24]. A prognostic factor is capable of 
providing information on clinical outcome at the time of diagnosis, which is usually 
independent of therapy and is often an indicator of growth, invasion, and metastatic 
potential [25, 26]. The most important role is that which helps to discriminate between 
a group of patients with good prognosis who do not require adjuvant systemic therapy 
after local surgery and a group with a poor prognosis for whom additional treatment is 
indicated. A predictive factor is capable of providing information on the likelihood of 
response to a given therapeutic modality, for example, hormone receptors which so far 
have been the best predictive tumor markers [25]. For example, lymph node status is an 
important prognostic factor, but does not supply information on the likelihood of 
response to therapy. There are, however, some makers which have both predictive and 
prognostic values. Of those, HER2 expression is a predictive factor since it indicates 
the likelihood of response to targeting therapy and is also a prognostic factor signaling 
poor prognosis. Recently, it has been described that markers such as cell proliferation, 
circulating tumor cells as well as circulating cell-free DNA and micro RNA and 
multigene signatures can be of value in the management of breast cancer patients [27]. 
Today, several factors in breast cancer are used in clinical practice for aiding choice of 
appropriate treatment [28]. 
  
1.2.1 Tumor size  
Tumor size is as an independent prognostic factor and larger tumors have been found to 
have negative effects on breast cancer-specific survival [29].  Tumor size predicts both 
relapse and distant relapse in non-operable stage [30].  Patients had a relapse-free 
survival rate of 91% at 10 years and 87% at 20 years for tumors <1 cm compared to 
73% and 68% for tumors greater than 1cm [31]. Variation in tumor size predicts 10-
year distant metastasis risk ranging from below 10% for tumors less than 10 mm to 
90% for tumors larger 30 mm [32].  An increased mortality rate was associated with 
larger tumor size (11-20 mm tumors vs. 1-10 mm tumors, standard morality ratios 
=1.42) in hormone receptor-positive breast cancer patients [33]. The prognostic impact 
of tumor size is partly related to the fact that tumor size is capable of predicting 
incidence of axillary lymph node metastasis, 10% in tumors less than 1 cm and 35% for 
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a tumor diameter of 1.6-2cm [34]. An increase in tumor size has been associated with a 
significant risk of lymph node metastasis in stage I [35, 36]. Tumor size is still an 
apparent independent factor for long-term survival and patients with larger tumors had 
lower survival rate [37, 38].  
 
1.2.2 Axillary lymph node 
As the axillary lymph nodes receive 85 percent of the lymphatic drainage from all 
quadrants of the breast, histologic examination of removed axillary lymph nodes is the 
most accurate method for assessing spread of disease [28]. 
Axillary lymph node status is one of the most important prognostic factors in women 
with early stage breast cancer [32, 39]. Lymph node metastasis has been assessed as a 
strong independent factor for both overall survival (OS) and disease free survival (DFS) 
[40, 41]. In addition, 5-year specific survival and disease-free survival rates were lower 
for patients with micrometastasis (pN1mi) than for those with node-negative disease 
(pN0) [42]. In multivariate analysis, the presence of occult metastasis in the lymph 
nodes was found to have a prognostic impact on survival as assessed by a 25-year of 
follow-up [37]. Postmenopausal women with more than 3-node metastasis have ten 
times higher mortality rate than those without node involvement [36]. The extent of 
node metastasis is also an important significant prognostic factor. The overall survival 
in patients with node metastasis was significantly lower in patients with extra-capsular 
tumor growth as compared to those with intra-capsular growth [43]. Even in advanced 
tumor stages, clinical node involvement was an independent factor for predicting 
relapse [30]. Thus, the number of metastatic nodes today is used as a guide to 
recommend adjuvant systemic therapy. Endocrine therapy alone is indicated for node 
negative patients with hormone receptor-positive tumors and adjuvant chemotherapy 
often being applied in those cases of patients with equal to or above 4 metastatic nodes 
[44]. Patients who with one to three positive axillary nodes have additional risk factors 
are considered, and patients with four or more positive axillary nodes is always 
recommended for adjuvant radiotherapy [28]. 
 
1.2.3 Histologic type 
Histological examination of cancer cell morphology and architectural patterns are of 
importance in defining tumor subtype. Invasive ductal carcinoma is the most frequent 
subtype and presents two thirds of all breast cancers. This cancer is aggressive and 
typically metastasizes to bone, lung and liver. The lobular subtype is found in 
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approximately 10% of patients and a better survival is expected if patients receive 
endocrine therapy as compared with patients with invasive ductal carcinoma [45]. 
Lobular carcinomas are more often low grade and patients have a better prognosis than 
those with ductal carcinomas [46]. The medullary type is typically hormone receptor-
negative, HER2(-) and p53(+) positive with an aggressive clinical behavior [47]. It is 
reported that about 5-7% of all breast cancers are of this type. Mucinous carcinoma is 
found in 3% of patients and tends to have a rather good prognosis. Papillary carcinoma 
represents 1-2% of all breast cancers and is in a majority of cases ER(+) and has a good 
prognosis. However, patients with a ductal or lobular infiltrating histological type had a 
poor prognosis compared with those with other subtypes [48]. 
 
1.2.4 Histologic grade 
Assessment of histologic grade: Tumor grade is defined as prognostic factor in breast 
cancer [49]. Invasive carcinomas are today graded according to Scarff-Bloom-
Richardson (SBR) or Elston-Ellis system; they are strongly correlated to overall and 
recurrent free survival [28, 50, 51]. The grading is based on the sum of scores assigned 
three histological features: degree of ductal differentiation, pleomorphism, and mitotic 
index.  
Prognostic value: A comparative report from France showed that both these two 
histological grade systems were strongly predictive for overall and disease-free 
survival. Assessment of 1,831 patients with operable breast cancer showed that patients 
with grade I tumors had a significantly better survival than those with grade II and III 
tumors [52]. Patients with low grade tumors had survival higher than high grade 
tumors, 9% and 20% in disease stage I and II, respectively [46]. Tumor grading was 
found to be the strongest independent prognostic factor for both OS and DFS in 
Malaysian [40] or breast cancer-specific survival in both Caucasian and African-
American population sampled [29]. Postmenopausal women with high grade tumors 
have eight times higher mortality as compared to those with low grade tumors [36]. A 
similar correlation was also seen for 10-year disease free survival in untreated young 
patients [53]. The tumor grade was also confirmed as an independent marker of long-
term survival in patients with lymph node negative disease [37]. High tumor grade was 
likely to predict regional metastasis and a 2.69 times increased risk of node metastasis 
was observed for high-grade tumors as compared with low-grade tumors [35]. In 
operable breast cancer, histologic grade was an independent predictor of both BCSS 
and DFS [54].  
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Predictive value: It has also been described that SBR tumor grade is a marker of 
chemosensitivity in invasive ductal breast carcinomas. Thus, grade III tumors 
responded better to neoadjuvant treatment than SBR grade I tumors, independently of 
type of chemotherapeutic regimens [50]. In patients treated with radiotherapy alone, 
histological grade was important for prediction of local and distant disease control [30]. 
High tumor grade was a significant predictor of distant recurrence in patients with 
node-negative and tamoxifen-treated breast cancer [55]. 
 
1.2.5 Estrogen receptor and progesterone receptor 
There are two kinds of hormone receptors, estrogen receptor (ER) and progesterone 
receptor (PgR), which are members of a nuclear hormone receptors superfamily that is 
located in the cytosol for operation of ligand-dependent transcription factors. There are 
two types of ER, (ERα and ERβ) of which ERβ is more widely distributed in the body 
than ERα , which is expressed mostly in the uterus and mammary gland [56]. The 
molecular weight for ERα is 65,000 Daltons and 54,000 Daltons for ERβ. Both proteins 
have five functional domains which include a DNA- and a ligand-binding domain. The 
ligand binding domain in ERα and ERβ shows 58% homology which may explain the 
different responses to various hormones and anti-hormones. Upon ligand binding, ERα 
and ERβ may form homo-dimers or heterodimers which after binding to DNA either 
activate or suppress genes. The role of ERα- and ERβ-driven pathways might change 
during breast tumorigenesis [57]. 
 Most reports on ER as a predictive or a prognostic factor are related to ERα content 
which is in excess over ERβ [58]. It has been reported that 62% of the tumors are ERα 
positive and 65% ERβ positive. ERα correlated positively with ERβ (p=0.001) [59]. 
Both forms are ER-regulated and mediate the effect of progesterone both in normal 
breast epithelium and breast cancer cells [60].  
Analysis of hormone receptors: Several techniques have been used to assess the 
hormone receptor content in breast cancer tissues [56]. There have been two major 
techniques for quantitation of ER and PR in clinical practice and they either involve the 
binding of a radiolabeled steroid ligand to the receptor, or the recognition of the 
receptor protein by specific antibodies.  
The ligand binding assay (LBA) was the first technique developed for analysis of ER 
and later PgR in tumor cytosolic fraction which was correlated with response to 
endocrine treatment [61]. The assay is based on binding of radioactive estrogen to the 
receptor protein in homogenized fresh tumor tissue. It measures the ER or content of 
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both epithelial, stromal cells in tumors. This quantitative technique allows analysis of 
many samples in a few hours and is very sensitive. The ligand binding assay has been 
the first method to evaluate the receptor content in clinical samples of breast cancer. 
The advantage of this technique was that it gave a quantitative receptor value with good 
reproducibility. There were, however, some disadvantages with the ligand binding 
assay. In the first place it requires fresh or frozen tumor tissue in quantity (at least 0.5-
1.0 cm) and fixed in liquid nitrogen at -70ºC and shipped on dry ice [62]. Moreover, 
this technique does not discriminate between tumor cells and benign cells which may 
result in low or false-negative results because of dilution effects. In addition, it is labour 
intensive and involves the use of radioactive material that is difficult to assess in less 
developed countries. The production of specific antibodies to the ER and PgR later led 
therefore to the development of new assay techniques. 
The enzyme immunoassay (EIA) is an assay based on specific anti-ER and anti-PgR 
antibodies [63]. The epitope of the receptor is recognized by the antibody which is 
linked to an enzyme. The intensity of the color is quantified spectrophotometrically and 
the receptor level is determined by comparison to a standard curve. This technique 
measures the receptor protein and requires fresh or frozen tumors with a size between 
0.5-1 cm in diameter. This technique has been used in Sweden since 1988 with the 
hormone receptor values defined as fmole of receptor normalized to DNA content as 
measured by the Burton method. In adjuvant  therapy, this method was validated in 
patients administered long term treatment of tamoxifen [64]. 
Immunohistochemistry (IHC) has rapidly become the predominant method for 
measuring ER and PR in clinical practice and it can be performed on a variety of 
samples including fine needle aspirates, core biopsies, fresh or frozen tissue and 
paraffin-embedded archival tissue. After evaluation in the light microscope, a semi-
quantitative receptor value is calculated based on staining intensity and percentage of 
stained cells. A distinct advantage is that the IHC assay only measures the ER and PgR 
content in cancer cells. Moreover, this method is today robust, cheap and easy to use in 
clinical routine work. Thus, IHC is used in most laboratories for measuring ER and 
PgR in clinical routine pathology [27, 28]. However, the definition of receptor 
positivity varies between different laboratories and several cut-off points have been 
suggested [63]. Thus, cut-off points between 1% and 25% have been suggested [56]. 
However, there is a trend to accept 10% as cut-off between negative and positive 
tumors.  
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An excellent agreement for positivity as determined between EIA (cut-off at 
0.10fmol/µg DNA) and IHC (cut-off at ≥10% cell stained) has been published [62, 63]. 
Newer techniques have been applied to assess hormone receptor status such as Real-
time polymerase chain reaction (RT-PCR) and ER messenger RNA or northern blot 
assay. RT-PCR has high concordance with IHC for ER and PgR status in surgical 
specimens [65]. However, these procedures are not yet recommended in daily clinic 
routine [28, 66]. 
Prognostic factor: The prognostic capability of ER had been described in early studies 
before ERβ was discovered. It can therefore be assumed that the prognostic value of ER 
is confined to ERα since this isoform is present in excess over ERβ in breast cancer cells 
[57]. In long-term follow-up, hormone receptor status has been identified as an 
independent prognosticator of outcome [38, 67-69] and an independent prognostic 
factor for both OS and DFS in Asia patients [40]. However, another cohort study from 
Sweden  failed to demonstrate a significantly prognostic value of ER at 5 years after 
diagnosis, in spite of lower survival in patients with ER negative tumors  [39] or at 10-
years post-diagnosis in untreated young patients [53]. Patients with double hormone 
receptor positive tumors had the best breast cancer-specific survival with a 50% of risk 
reduction of breast cancer death compared to those with ER/PgR(-) tumors. Hormone 
receptor status was identified therefore as an independent prognostic factor of 
outcome [67], which was also observed for postmenopausal women [36]. Although 
patients with hormone receptor-negative tumors received greater benefit from 
neoadjuvant chemotherapy in terms of pathologic response, they have worse outcomes 
in terms of recurrence and survival as compared to hormone receptor-positive patients 
[70]. However, PgR status is reported as a prognostic factor for survival but not ER 
with 25-year of follow-up [37]. Today, it is accepted that the prognostic information by 
ER is not sustained at long-term follow-up. These conflicting results may be explained 
by small patient series, short follow-up, various techniques for ER analysis and the lack 
of standard cut-off points between receptor positivity and negativity. The prognostic 
value of PgR alone is less well documented. A report from Sweden showed that PgR 
level was an independent factor in patients without systemic adjuvant treatment [32].  
Predictive value: while the prognostic role is still a controversial issue, the predictive 
value of hormone receptor status is well defined. Receptor positivity will predict 
response to endocrine treatment in 75-80% of patients with ER(+) tumors as compared 
with less than 10% of those with ER(-) tumors [71]. The predictive value of tumor 
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receptor content has been verified for both premenopausal and postmenopausal patients 
and in both advanced and early stage breast cancer [27, 28]. In a recent review of 
randomized studies, it was concluded that patients with ER(+) tumors had a 31% death 
risk reduction if treated with tamoxifen for 5 years, but had no effect on survival in 
ER(-) patients as reported from the Early Breast Cancer Trial’ Collaborative Group 
[68]. Hormone receptor status has also been described as a predictive factor for 
chemotherapy responsiveness: thus, both total and pathologic complete response rates 
were higher in hormone receptor negative patients (26% and 32%, respectively) than in 
hormone receptor-positive patients (4% and 7%, respectively; p<0.001) [70]. ER(-) 
tumors are better severed by chemotherapy. In patients treated with chemotherapy, the 
5-year disease free survival rate was 23% for patients in the ER(-) tumors category 
vs.7% for patients whose tumors were ER(+) [69]. The predictive value of PgR is less 
clear. In patients with inflammatory cancer, ER(+) tumors are more sensitive to 
anthracycline-based chemotherapy [72].   
Knowledge about ER/PgR status helps to select appropriate treatments in clinical 
practice. Therefore, it should be measured on primary breast cancer tissue and 
metastatic lesion if possible [27]. Tumors with expression of ER and/or PgR in as low 
as 1% of the tumor cells may respond to endocrine treatment but some studies suggest 
that 10% should be used as a cut-off. Notably, if patients whose tumors contain low 
levels of ER by IHC as classified as weak positive (1% to 10%) should be discussed 
before a decision of treatment is made [66]. Patients with uncertain or hormone 
receptor-negative tumors are often recommended to be administered adjuvant 
chemotherapy [28]. 
 
1.2.6 HER2 status 
The HER2 oncogene is located in chromosome 17 that encodes for a 185 KD 
transmembrane glycoprotein receptor belonging to the epidermal growth factor 
receptor  (EGFR) family including HER1/EGFR, HER2, HER3 and HER4 [73, 74], 
which are crucial in the activation of subcellular signal transduction pathways 
controlling epithelial cell growth, regulation of cell proliferation, differentiation and 
survival. Epithelial cells express around 20,000 HER2 receptors on their cell 
membranes. A fraction of breast cancers overexpress the HER2 receptor as a result of 
gene amplification which results in a 100-fold increase of the protein on cell 
membranes [26, 74]. So far, no specific ligand has been identified for HER2 but 
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specific antibodies to the receptors have been produced. Such antibodies suppress 
HER2- stimulated growth both in vitro and in vivo [75]. 
Assays for HER2: Procedures for measurement of HER2 protein are Western blotting, 
enzyme linked immunosorbent assay (ELISA) and immunohistochemistry (IHC). In 
IHC, the membrane staining patterns are identified as negative (0 or 1+) or positive 
(3+) and equivocal (2+). There are several methods to assess amplification of the 
HER2 oncogene such as fluorescence in situ hybridization (FISH), chromogenic in 
situ hybridization (CISH), silver enhanced in situ hybridization (SISH) and 
polymerase chain reaction (PCR) [76, 77]. In recent years, SISH has emerged as a 
new method which uses light microscopy and allows assessment of HER2 gene status 
with a high concordance with FISH [77, 78]. Today, it is generally accepted that in 
situ hybridization or PCR better define HER2 amplification than various protein 
measurements. The level of discordance in HER2 status paired primary tumor and 
metastasis is noteworthy [79]. It seems reasonable to reanalyze HER2 in tissue from 
recurrent lesions; particular if the primary tumor is negative or weakly positive. 
Prognostic value: women with HER2 gene amplification have poor prognosis. HER2 
amplification has been identified as an independent prognostic factor in breast cancer 
with lymph node metastasis and is also associated with other poor prognostic factors 
[80, 81]. It also predicted shorter disease free and cancer-specific survival in ER(+) 
patients but not in ER(-) cases [53, 82]. Overexpression of HER2 protein also 
influences in outcome of treatment in patient with ER(+) tumors treated with adjuvant 
endocrine therapy [82], which was also a negative prognostic factor in untreated 
patients with ER(+) tumors . 
Amplification of HER2 oncogene in tumors and metastatic lymph nodes may be a 
useful independent marker of poor prognosis and correlated with tumor recurrence 
and shorter survival in early stage [38, 83]. The HER2 oncogene was an independent 
prognostic factor for DFS in premenopausal women with node negative disease [84]. 
However, HER2 overexpression did not adversely influence response to adjuvant 
oophorectomy plus tamoxifen treatment in patients with estrogen receptor-positive 
tumors [85] and notably, in a population from Asia [40]. It has been suggested that 
patients with HER2 positive early breast cancer should be treated with adjuvant 
therapy with trastuzumab and chemotherapy [28]. 
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Predictive value: women with a high level of HER2 protein expression or an 
amplified HER2 gene benefit from treatment by HER2 antibody such as trastuzumab 
(Herceptin) and lapatinib, both in the adjuvant and metastatic disease settings [27, 
86]. Addition of neoadjuvant trastuzumab for HER2(+) tumors results in a superior 
response irrespective of hormone receptor status [70]. Furthermore, HER2 status is 
also likely to predict sensitivity to chemotherapeutic agents. Thus, tumors with HER2 
overexpression potentially have good response to anthracycline-based regimen [27, 
74, 87] and little resistance to paclitaxel treatment alone, but get more benefit if in 
combination with AC regimen [88] and have improved survival with CMF regimen 
[89]. In contrast, HER2 negative inflammatory cancers were reported more sensitive 
to anthracycline-based chemotherapy [72]. The role of HER2 status to predict 
endocrine therapy is still conflicting, while an inverse correlation to tamoxifen 
response has been described [71, 90, 91]. This correlation does not seem to exist in 
premenopausal patients [53, 85].  It is considered nowadays to be indicated with 
trastuzumab both in the adjuvant and metastatic disease settings for patients with 
HER2-amplified tumors. It has been described that the HER2 status can show 
disagreement between primary and recurrent tumors which likely influence response 
to therapy [79]. Recently, the panel of the St Gallen international breast cancer 
conference strongly supports that HER2, together with hormone receptor status, is 
useful in defining subtypes of breast cancer [92].  
 
1.2.7 Cell proliferation 
The proliferative rate of breast cancer has been assessed by various methods, including 
mitotic index, thymidine labeling index, bromodeoxyuridine labeling, S-phase fraction 
determined by flow cytometry and IHC using monoclonal antibodies to antigens 
associated with proliferation of cells, for instance Ki67 [93, 94]. Most recent studies 
have however assessed cell proliferation by determining S-phase fraction using flow 
cytometry or Ki67 staining. The Ki67 protein is a nuclear protein doublet, 345-395 
kDa, playing a pivotal role in maintaining cell proliferation. Ki67 is present in all non-
G0 phases of the cell cycle. Beginning in the mid-G1, the level increases through S and 
G2 to reach a peak in M. In the end of M phase, it is rapidly catabolized. The Ki67 
labelling index is defined as the percentage of cells in a tissue with nuclear staining for 
Ki67 with different antibodies, such as MIB-1 and K-2 [94-96]. The median value for 
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MIB-1 staining shows large variations in breast cancers with figures of less than 10% 
up to values above 20% [97].  
Prognostic value: The rate of cancer cell proliferation measured by Ki67 has also been 
shown to be a good prognostic factor. Ki67 index showed a significant relation with 
survival in node-positive patients [38]. Klintman et al found that a proliferation rate 
over 20% was correlated to a worse prognosis in premenopausal patients with node-
negative breast cancer [84]. The usefulness of Ki67 as a prognostic marker in early 
breast cancer has been shown in a recent meta-analysis involving 12,155 patients 
[98]. Another study found that the rate of proliferation was only an independent 
prognosticator if other factors such as age, tumor size, histological grade and nodal 
status were co-analyzed [99]. Recent findings confirmed that Ki67 expression in 
metastatic lymph nodes was an independent factor for disease-free survival [38] and 
this marker could be considered to add prognostic information on the risk stratification 
with the use of the St. Gallen consensus guideline [100]. Thus, it is presently 
recommended to assess cell proliferation as a part of the pathological routine work-up 
[28].  
Predictive value: The rate of cell proliferation as measured by Ki67 staining is an 
important parameter in vitro for the selection of treatment strategies aimed at inhibiting 
cell proliferation [94]. Recent studies on the Ki67 index as a biomarker for response to 
chemotherapy have shown that it is an important marker for both neoadjuvant therapy 
and metastatic settings [24, 101]. Patients with a Ki67 index of less than 15% benefited 
from endocrine therapy in contrast to those with higher Ki67 indices [102]. Recently, 
the St Gallen international breast cancer conference recommended the use of 
proliferation, such as Ki67 staining to select optimum treatment for early breast cancers 
[44, 92]. Though other markers of cell proliferation, such as MI, TLI and S-phase 
determination by DNA flow cytometry, have a significant correlation with other 
clinicopathologic factors they do not appear useful in routine clinical work. The 
American Society of Clinical Oncology (ASCO) tumor marker expert panel did not 
recommend the use of S-phase or other flow cytometry techniques to assign patients to 
prognostic groupings [27]. Today, these techniques have however, to a large extent, 
been replaced by immunohistochemical analysis of Ki67. Guidelines for diagnosis and 
treatment recommend the use of Ki67 staining for pathologic work-up in clinical 
practice to guide systemic treatment [28, 44]. 
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1.2.8 Internationally approved combination of prognostic 
and predictive factors 
1.2.8.1 TNM grouping system  
 
Table 1: Anatomic stage/prognostic groups [28] 
Stage 0 — Tis N0 M0 
Stage I — T1 N0 M0 (including T1mic) 
Stage IIA — T0 N1 M0; T1 N1 M0 (including T1mic); T2 N0 M0 
Stage IIB — T2 N1 M0; T3 N0 M0 
Stage IIIA — T0 N2 M0; T1 N2 M0 (including T1mic); T2 N2 M0; T3 N1 M0; T3 N2 M0 
Stage IIIB — T4 N0-2 M0 
Stage IIIC — Any T N3 M0 
Stage IV — Any T Any N M1 
Definition: T-tumor size (cm), N-lymph node, M-distant metastasis.  
 
Clinical and pathologic stages consist of factors which reflect on extent of disease 
which is strongly prognostic. The TNM stage is apparent to add prognostic factors at 5-
year relative survival. The 5-year relative survival rates were 96% for Stage I, 86% for 
Stage II, 59% for Stage III and only 26% for Stage IV [46]. 
1.2.8.2 Nottingham prognostic index    
The Nottingham prognostic index (NPI) which combines nodal status, tumor size and 
histological grade, has been validated by further studies in Nottingham and by 
associated studies in several other countries [103]. NPI = Lymph node Stage (1-3) + 
histologic grade (I-III) + tumor size (cm) × 0.2, if NPI <3.4: good prognosis, 3.4-5.4: 
moderate prognosis and >5.4: good prognosis. One study from a Nottingham hospital 
reported that 15-year survival was related to NPI-good prognosis, moderate prognosis 
and poor prognosis, as 80%, 42% and 13%, respectively, [104]. Similarly, this index 
was confirmed as an independent prognostic factor 10-year survival reduced from 88% 
in the good prognostic group to 40% in poor prognostic group [48]. In recent years, 
NPI has been shown to be a reliable prognostic tool in triple negative breast cancer 
[105]. 
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1.2.8.3 Prognostic factors as markers for selecting treatment modalities      
Based on all approved prognostic and predictive factors, the expert panel of the St. 
Gallen Consensus Conference agreed to recommend a guideline for treatment practice 
[44]. 
 
Table 2: Threshold for treatment modalities based on prognosticators 
Clinicopathological 
features 
Relative indications for 
chemoendocrine therapy 
Factors not useful 
for decision 
Relative indications for 
endocrine therapy alone 
ER and PgR Lower ER and PgR level 
 
Higher ER and PgR 
level 
Histological grade Grade III Grade II Grade I 
Proliferation High
*
 Intermediate* Low* 
Nodes 
Node positive (≥4 
involved nodes) 
Node positive (1-3 
involved nodes) 
Node negative 
PVI Presence of extensive PVI 
 
Absence of extensive 
PVI 
pT size >5 cm 2.1-5 cm ≤2 cm 
Patient preference 
Use all available 
treatments  
Avoid chemotherapy-
related side effects 
Multigene assays 
   
Gene signature High score Intermediate score Low score 
 *Conventional measures of proliferation include assessment of Ki67 labeling index (e.g. low, 
≤15%; intermediate, 16-30%; high, >30% 
 PVI: peritumoral vascular invasion.  
 
1.2.8.4 Adjuvant online (www.adjuvantonline.com) 
Adjuvant online, which was developed in the United States, is an internet-based 
computer program providing 10-year prognosis predictions for early breast cancer 
patients.  When information is entered of patient's age, ER status (positive, negative, 
undefined), tumor grade (I,II,III, undefined), tumor size (0.1-1 cm, 1.1-2 cm, 2.1-3 cm, 
3.1-5 cm, >5 cm), and the number of positive nodes (0, 1-3, 4-9, >9), predictions are 
obtained of 10-year OS, BCSS, and DFS. According to a cohort study, predictions of 
adjuvant for all three outcomes were significantly greater than the observed outcomes. 
The difference between predicted and observed was 5.54% (P<0.001), for BCSS, 
4.53% (P<0.001), and for DFS, 3.51% (P=0.001) [106]. But this model predicted and 
observed outcomes were within 2% for most demographic, pathologic, and treatment-
defined subgroups, except in women younger than age 35 years [107]. However, 
adjuvant online needs to be updated to adjust overoptimistic results in young and high 
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grade patients, and should consider new predictors such as Ki67, HER2 and mitotic 
index [108]. Again, 10-year mortality predictions according to adjuvant online are 
most sensitive to comorbidity levels, particularly among older women from the US 
[109]. Thus, this model should be based upon validation in other ethnic populations 
worldwide. 
 
1.2.9 Other prognostic factors 
1.2.9.1 Oncotype DX 
Oncotype DX or recurrence score (RS) can be performed on formalin-fixed tissues, 
and is a RT-PCR based assay. The levels of expression of 16 cancer-related genes and 
five reference genes were used in a prospectively defined algorithm to calculate a 
recurrence score and to determine a risk group (either low, intermediate, or high) for 
each patient, which so far is among the best prognostic assays [110, 111].  
Prognostic value: Initially, it was found that RS could predict prognosis in node 
negative patients treated with tamoxifen alone. Thus, 93% patients with low RS (<18) 
were free of distant disease as compared with only 70% of those with high RS (>31) 
[55]. This marker is recommended by the ASCO for use in practice in women with 
node-negative, ER(+) breast cancer [27]. The recurrence score (RS) was an 
independent significant predictor of recurrence along with age and type of initial 
treatment. Recurrence was 4% for patients with a low RS (<18), 7.2% for those with 
intermediate RS (18-30), and 15.8% for those with a high RS (>30) after 10 years of 
tamoxifen treatment. It is recommended to determine RS for loco-regional 
radiotherapy in node-negative and ER(+) patients [110]. Together with a prognostic 
value, it has also been reported that Oncotype DX could predict chemotherapy 
response. 
Predictive value: The Recurrence Score was positively associated with the likelihood 
of response of neo-adjuvant paclitaxel and doxorubicin in advanced stages [112]. 
Gene expression also predicts benefit from chemotherapy in women with node-
negative, estrogen receptor-positive breast cancer. Patients with high-RS (≥31) 
tumors (i.e., high risk of recurrence) had a large benefit from chemotherapy [111]. 
The Panel from St the Gallen conference agreed that this predictive factor could be 
used for selecting chemo-endocrine therapy in patients with ER-positive, HER2-
negative early stage breast cancer [44], whereas the role of RS in hormone receptor-
negative and HER2-positive breast cancer is less clear. 
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1.2.9.2 Mammaprint 
Mammaprint uses the expression of 70 genes analyzed to identify patients with poor 
(high risk) or good prognostic (low risk) signatures. Gene expression was a strong 
independent factor for survival of early breast cancer patients and was particularly 
strongly associated with outcome in patients with node positive disease [113]. In Stage 
II-III patients, poor prognostic signatures cancer had 20% completed response to 
neoadjuvant chemotherapy whereas no patient with good prognostic signatures 
achieved. Tumors with a poor prognostic signature are more sensitive to chemotherapy 
[114]. The 70-gene signature is an apparently independent prognosticator for 
clinicopathologic risk assessment in patients with early breast cancer since this also 
predicts responsiveness to conventional chemotherapeutic regimens [115]. Despite 
concerns as to validity, Mammaprint has been cleared as a tool to assess the risk of 
disease recurrence in women with node-negative breast cancer. The expert panel from 
ASCO concluded that the clinical utility and appropriate application of Mammaprint 
need to be established. Thus, until now this marker has not been sufficiently established 
and trials are required to clarify this role [27, 92]. 
1.2.9.3 Other markers 
Several other factors are defined as prognosticators. In early history, p53 protein 
accumulation was assessed as an independent prognostic factor and associated with 
metastasis-free and overall survival [116]. Vascular endothelial growth factor 
(VEGF) is valuable to predict both general DFS (P=0.0289), OS (P=0.0004) and in 
patients who received adjuvant endocrine therapy (DFS, P=0.0238; OS, P=0.0121). 
This factor can also contribute to predict metastatic sites [117]. The level of cyclin E 
expression by IHC was an independent prognostic factor for relapse-free survival 
(DFS, HR 1.72) and for breast cancer-specific survival (HR 2.86) but not for DFS 
[118]. Detection of disseminated tumor cells (DTCs) in bone marrow was an 
independent prognostic factor for DFS and OS in patients with Stage I to III breast 
cancer [119]. Furthermore, circulating tumor cells (CTCs) were found to be an 
independent prognostic factor for early relapse but did not predict treatment response 
[120]. However, measurement of CTCs should not be used to decide treatment in 
early stage or metastatic disease [27]. The markers described above and other markers 
such as cyclin D, p27, p21, thymidine kinase or topoisomerase II, DNA content 
(ploidy) and S-phase are at present not recommended in routine clinic [27, 28]. Their 
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clinical role has, however, not yet been defined in larger series of patients but it 
seems likely that they will be of importance in the future. 
 
1.3 TREATMENT FOR BREAST CARCINOMA 
Methods for treatment are today dependent on several factors such as stage of disease, 
patient and tumor characteristics [28]. 
 
1.3.1 Surgery 
Surgery is crucial in management of breast cancer patients. Modified radical 
mastectomy refers to the complete removal of the breast and the underlying fascia of 
the pectoralis major muscle along with the removal of the level I and II axillary lymph 
nodes. Breast cancer surgery has changed dramatically over the last 20 years. Breast 
conservative therapy (BCT) is defined as removal of the tumor without removing 
excessive amounts of normal breast tissue which leads to a cosmetically acceptable 
result with a low rate of local recurrence. Breast cancer survival after breast 
conservative surgery is equal to total mastectomy [121]. Traditionally, an axillary 
lymph node dissection (ALND) was recommended in every patient with invasive breast 
cancer. Currently, ALND remains the standard approach for patients who have 
clinically palpable axillary nodes. Completion of ALND is also indicative in patients 
who have positive sentinel lymph node biopsies since there is a risk that additional 
nodes are involved  [28]. Sentinel lymph node biopsy (SLNB) is indicated for patients 
with clinically axillary node-negative early breast cancer. With remarkably improved 
screening techniques and the introduction of sentinel node biopsy techniques, the 
indications for axillary dissection have diminished in European countries [122]. 
Sentinel lymph node biopsy results lower morbidity and better quality of life as 
compared with standard axillary treatment [123]. Notably, the overall false-negative 
rate for sentinel lymph node biopsy was reported as 7.7% in 20 hospitals in Sweden 
which often was due to multifocal tumors. However, it was shown to be a reliable 
method for axillary staging of unifocal breast tumors [124]. Sentinel lymph node 
biopsy is currently accepted as the standard of care for axillary staging in early breast 
cancer unless axillary node involvement is suspected clinically or on ultrasound [28]. 
Surgical oophorectomy, either with open or laparoscopic procedures, causes an 
immediate and permanent drop in ovarian steroid production for premenopausal 
patients with hormone receptor-positive tumors. In women with a known or suspected 
breast cancer susceptibility gene (BRCA) mutation, it may be a component of adjuvant 
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treatment. Breast reconstruction following mastectomy improves psychological health 
and quality of life [125]. Breast reconstruction can be performed at the time of the 
mastectomy or at a subsequent operation. There are two general types of reconstructive 
options: implant-based techniques and autologous tissue reconstructions with tissue 
flaps. 
 
1.3.2 Radiotherapy 
Postoperative radiotherapy not only decreases the risk of loco-regional recurrence 
including axilla, supraclavicular and internal mammary nodes but also improved 
survival in high-risk postmenopausal breast cancer patients after mastectomy. The 
absolute reduction of loco-regional recurrence was 27% after 123 months of follow-up 
[126]. However, in a premenopausal population, post-mastectomy radiotherapy 
reduced loco-regional recurrences but did not reduce mortality with 20 years of 
follow-up [127]. Postoperative radiation reduces local recurrence after lumpectomy 
from 39% to 14% at 20 years [128]. The addition of radiotherapy to surgery resulted in 
a rate of local recurrence that was three times lower than surgery alone [129]. In the 
subset of patients with T3N0 disease, adjuvant radiotherapy improved OS from 33% to 
40% and increased the 10-year DFS rate to 15% [126]. The benefit of adjuvant 
radiotherapy was also seen after 5 years in patients with Stage I-II lymph node negative 
breast cancer and the disease-free survival (DFS) was significantly higher after 
postoperative radiotherapy, 88% vs. 77% [130]. One overview of randomized trials 
reported that radiation therapy reduces 5-year local recurrence with 17-19% and 15-
year breast cancer mortality by 5.4% in both node negative and node positive disease 
[121]. Post-mastectomy radiation therapy was strongly indicated for patients with 
four or more axillary lymph nodes metastasis and for patients younger than 45 years 
with 1-3 positive nodes as well as patients at any age with extensive vascular invasion 
in two or more blocks in conjunction with 1-3 positive nodes. Whole breast 
radiotherapy reduces the risk of local recurrence by two-thirds and an additional boost 
gives a further 50% risk reduction. Additionally, radiotherapy has a beneﬁcial effect 
on survival. The recommendation is at present 45-50 Gy for entire breast treatment 
for use of eradicating microscopic residual foci of breast carcinoma, and an additional 
boost up to 60-65Gy to the tumor bed. Notably, this method of treatment is not 
indicated for elderly patients with good prognosis. Recently, partial breast irradiation 
(PBI) is a new approach that early results are promising. However, long term follow-
up will be needed to confirm these results before partial breast radiotherapy is 
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accepted as a routine procedure. The Panel of the 12th International Breast Cancer 
Conference generally accepted PBI as an alternative to conventional external beam 
boost to the tumor bed [28]. 
 
1.3.3 Chemotherapy 
Adjuvant chemotherapy: following primary surgery for breast cancer the elimination 
of possible clinically occult micrometastasis is attempted. Systemic adjuvant 
chemotherapy plays a major role in improving survival of breast cancer patients [68]. It 
is of importance to estimate the risk for recurrence or presence of metastasis in 
individual patients and the likelihood that they will benefit from adjuvant 
chemotherapy. Until now, clinicopathologic prognostic factors such as patient age, 
tumor size, histologic grade, lymphovascular invasion, axillary lymph node status, 
hormone receptor status, and HER2 expressions have all been used to aid treatment 
decision.  
Table 3: Table of selected current adjuvant chemotherapy regimens, adapted from 
ESMO guidelines 2011 [28].  
Regimen No. of cycles 
Duration of cycles 
(weeks) 
 
AC 4 3  
CMF (oral or IV. days 1+8) 6 4  
FE100C  6 3  
CE1,8F  6 4  
A (or E)→CMF 4→4 (–8) 3→4  
AP→CMF 4→4 3→4  
DC 4 3  
AC→P(H) qwk 4→4 3→3  
AC→D(H) 4→4 3→3  
DCarboH 6 3  
ddAC→ddP (G-CSF) 4→4 2→2  
DAC 6 3  
FEC100→D  3→3 3→3  
A, doxorubicin; C, cyclophosphamide; D, docetaxel; E, epirubicin; F, fluorouracil; G-CSF, granulocyte 
colony-stimulating factor, e.g. filgrastim; M, methotrexate; P, paclitaxel; Carbo, carboplatin; H, 
trastuzumab, may be given with a taxane; qwk, weekly; dd, dose-dense; →, followed by.  
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One study showed that women younger than 50 years of age treated with six months 
of adjuvant anthracycline-based chemotherapy, irrespective of hormone receptor 
status, reduced the 15-year probability of recurrence (from 54% to 41%) and breast 
cancer mortality (from 42% to 32%). For women aged 50 to 69 years, treatment 
reduced the 15-year probability of recurrence (from 58% to 53%) and breast cancer 
mortality (from 50% to 47%). The absolute benefit of chemotherapy is thus about 
three times greater for young as compared to old women [68]. Adjuvant systemic 
therapy appears to provide additional local tumor control after conservative surgery. 
At present, anthracycline is recommended for most patients and especially for 
patients with HER2(+) tumors except for elderly patients or those with heart 
problems [74]. Clinicopathologic features which convey a relative indication for 
chemotherapy include ER negativity, grade III tumors, elevated cell proliferation 
determined by Ki67 staining, four or more lymph nodes positive, peritumoral 
vascular invasion, tumors greater than 5 cm and patient preference [131]. 
Neoadjuvant therapy: Neoadjuvant chemotherapy is normally indicated for locally 
advanced breast cancers (Stages IIIa-c) or inﬂammatory breast cancer (Stage IIId) and 
for large or inoperable tumours for reducing tumour size in order to perform BCS 
[132]. One advantage is that response can be monitored, thereby allowing the 
continuation of effective therapy or change to other regimens when indicated. 
Moreover, patients with loco-regional tumor control are likely to have a higher DFS 
rate [133]. In addition, preoperative chemotherapy reduces disease stage [134]. This 
study showed that tumor size was reduced in 80% of patients after a preoperative AC 
regimen and 36% had a clinical complete response. In women with tumors ≥5 cm, 
preoperative chemotherapy made breast-conserving surgery possible in 20% of 
patients who were not initially eligible. Together, clinical positive node responded in 
89% of cases in which 44% of those had a pathological completely remission. 
Clinical measurement of breast masses is often used to assess the response to 
neoadjuvant chemotherapy according to WHO (World Health Organization)/UICC 
(Union for International Cancer Control) criteria.  
 
1.3.4  Endocrine therapy 
Over the last 35 years, the selective estrogen receptor modulator tamoxifen became 
the standard of care in the Western world for metastatic hormone receptor-positive 
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tumors in both premenopausal and postmenopausal women due to its more favourable 
safety profile. 
In patients treated with breast conservative surgery with node-negative breast cancer, 
the Stockholm Breast Cancer Study Group found that the ten-year rate of local 
recurrence was significantly less in women receiving tamoxifen (3% vs. 12%)  [135]. 
For patients with ER(+) tumors, five years of adjuvant tamoxifen reduced the 15-year 
probability of recurrence (from 45% to 33%) and breast cancer mortality (from 35% 
to 26%) [68] While the absolute risk reduction after five years of tamoxifen was 
similar for women younger than 50 years and women above 50 years (10% vs. 12%), 
it was more pronounced for those with node-positive than node-negative disease 
(16% vs. 9%). Relative-risk of relapse in ER(+) patients treated with tamoxifen was 
lower than those with ER(-) (HR 0.77, CI 0.63-0.93) [71]. Tamoxifen treatment even 
only 2 years improved survival in ER(+) premenopausal patients [53]. Using 
tamoxifen therapy for 5 years instead of 2 years was found to be beneficial for 
patients with ER(+) and PgR(+) early stage, invasive breast cancer [136]. Today 
tamoxifen with a standard dose of 20mg per day is a current appropriate first-line 
agent in premenopausal women who have never received tamoxifen or who relapse at 
least 12 months after completion of adjuvant tamoxifen [28].  
However, tamoxifen resistance is problem which related to reduce CYP2D6 activity 
[137]. Aromatase inhibitors including anastrozole, letrozole, or exemestane should be 
currently administrated for patients who had contraindication to tamoxifen. One 
multicentre clinical trial claimed that early breast cancer postmenopausal patients 
treated with anastrozole had higher DFS compared to tamoxifen and also associated 
with a prolonged time to recurrence (absolute difference of 2.8% at five years, and 
4.8% at 9 years), reduced distant metastases, and fewer contralateral breast cancers 
but not significant difference in deaths after recurrence [138]. Duration of tamoxifen 
or aromatase inhibitors, alone or sequentially, is currently used for at least 5 years. 
Most premenopausal women with early stage hormone receptor-positive breast cancer 
can be treated with ovarian suppression/ablation, alone or combined with tamoxifen 
that is clearly superior. The choice of treatment is individualized according to patient 
preference, whereas, ovarian suppression/ablation in combination with aromatase 
inhibitor is at present not recommended [131]. 
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1.3.5 Targeted therapy 
Patients with either HER2 protein overexpression determined by IHC staining or 
HER2 gene amplification by FISH/CISH/SISH are  treated with targeted therapy such 
as trastuzumab, both in the adjuvant and metastatic disease setting [27, 28]. 
Trastuzumab (Herceptin
®
) is a human monoclonal antibody (MoAb) that binds to a 
specific epitope of the HER2 protein on the cell surface. This interaction inhibits 
signal transduction induced by other peptide growth factors interacting with their own 
receptors [74]. The consequence is inhibition of cancer cell growth. Additionally, it 
has also been shown to enhance the TNF-alpha sensitivity of breast tumor cells that 
overexpress this proto-oncogene [139]. Trastuzumab is initially indicated for 
metastatic disease with strong (3+) IHC for HER2 protein product or HER2 gene 
amplification by FISH and is now the first-line choice for these patients in practice.  
 
 
Fig. 2: Interactions between trastuzumab and cancer cells, adapted from [74] 
 
The overall response rate was seen in 35% of patient with (3+) but was not in patients 
with (2+) tumors. The use of trastuzumab in patients with HER2(+) breast cancer can 
lead to increased survival. In HER2(+) advanced stage, neoadjuvant trastuzumab 
results in pathologic complete response as compared to those without HER2 
positivity (37% vs. 17%; p=0.02) in breast, (47% versus 23%; p=0.05) in lymph 
nodes [70]. Furthermore, lower recurrence rates (5% vs. 42%; p<0.001) and increased 
overall survival (97% vs. 68%; p<0.001) were also observed. In HER2(+) metastatic 
breast cancers, chemotherapy plus Trastuzumab is recommended rather than 
trastuzumab alone. However, this treatment is not usually indicated for patients with 
HER2(-) [140]. 
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In patients with HER2(+) locally advanced or inflammatory breast cancer, the 
combination of trastuzumab to neoadjuvant chemotherapy improved disease-free 
survival, survival, and clinical and pathological tumour responses [141]. In early 
stage disease, the international multicentre randomized (HERA) trial stated that 
Trastuzumab improved in 3-year DFS up to 11.3% and reduced death risk with 36% 
vs. without Trastuzumab. Additionally, trastuzumab reduced the risk of relapse [142]. 
The DFS and OS rates at 5 years were higher among those receiving anthracycline-
cyclophosphamide plus taxane in combination with trastuzumab as compared to those 
without (84% vs. 75%; 92% vs. 87%, respectively). Trastuzumab thus improves 
survival in either combination with anthracycline or taxane [143]. Trastuzumab can 
be administered concomitantly with taxane or vinorelbine [144]. The 
recommendation for one year treatment with Trastuzumab can be considered in 
combination with polychemotherapy [142, 143]. Anthracycline-containing regimen 
plus trastuzumab may have cardiotoxic effects. It is important to avoid trastuzumab in 
patients with low left ventricular ejection fraction (LVEF, <50%–55%) and in 
patients whose cardiac function deteriorates during therapy [28].  
Lapatinib is an orally active tyrosine kinase inhibitor that blocks HER2 as well as 
other members of this receptor family which was approved to use for women who 
progressed on trastuzumab and were chemorefractory [145]. A combined regimen of 
lapatinib plus capecitabine had an improved overall response rate (24% vs.14%) but 
showed no significant effect on survival [146]. Lapatinib plus letrozole as first line 
treatment in HER2(+) patients with metastatic disease failed to improve overall 
survival despite improvement of median progression-free survival [147] and 
Lapatinib seems better than Trastuzumab in patients with brain metastasis. Lapatinib 
is currently being evaluated in both the adjuvant and metastatic setting and was 
recently approved by the United States Food and Drug Administration, in 
combination with capecitabine, for the treatment of women with HER2-positive, 
pretreated, metastatic breast cancer [148].  
Another targeting agent named Avastin is a monoclonal antibody (MoAb) against 
vascular endothelial growth factor (VEGF), arguably the most important regulator of 
tumor angiogenesis of the EGFR family. However, this agent has been revoked the 
approval for metastatic breast cancer in the United States (http://www.fda.gov) 
because of failure in efficacy. 
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2 RATIONALS FOR THIS THESIS 
 
Previous reports on breast cancer from pathology departments from various hospitals in 
Vietnam reported ER, PgR positivity and HER2 overexpression in the ranges 55.2-
59.1%, 39.2-51.4% and 35.1-44.2%, respectively. However, none of these studies 
analyzed the correlation to clinical characteristics [149, 150]. In one study it was found 
that 26% of Vietnamese premenopausal patients with hormone receptor-positive 
tumors had HER2 protein overexpression [85]. 
Several studies on breast cancer in women living in the USA found that Vietnamese as 
well as Asian women had different tumor cell characteristics as compared with women 
of Caucasian or Hispanic origin [4, 7, 17, 151]. Similarly, a number of studies indicated 
that breast cancer from Afro-Americans more often had poor prognostic factors than 
had Caucasian-American and that tumor characteristics vary among Asian ethnicities 
[18, 152]. One comparative study stated that breast cancers from Korean patients more 
often had unfavorable factors compared to other American patients [153]. A recent 
report from the USA showed different treatment outcome because of different 
characteristics of breast cancers among ethnicities [152]. One study performed in the 
National cancer hospital revealed that Vietnamese breast cancer patients had the 
lowest frequency of BRCA mutations worldwide [154].Thus, several studies indicated 
that tumor cell characteristics of breast cancer varied between patients of different 
ethnicities. Up until this study, there is no report describing prognostic and predictive 
factors for Vietnamese women with breast cancer. From the above cited reports, it 
seemed likely that Vietnamese breast cancer patients might have different profiles for 
prognostic and predictive factors as compared to Swedish patients. If so, the question is 
to what degree they are different and if there were differences how would this affect the 
choice of treatment and clinical outcome. 
   25 
3 OVERALL AIMS  
 
This study aimed to investigate prognostic and predictive markers such as hormone 
receptors, HER2 expression and cell proliferation in operable breast cancers sampled 
from Vietnamese women and then correlated them with clinicopathologic factors and 
outcomes. A comparison of these factors was also made with a counterpart sample of 
operable breast cancers in Swedish women treated in Karolinska University Hospital 
and in Stockholm region. 
 
 SPECIFIC AIMS: 
1. To analyze the estrogen and progesterone receptor content in operable breast cancers 
from Vietnamese women and make a direct comparison with the receptor profiles in 
Swedish patients treated over the same period of time (Study I). 
 2. To assess the HER2 status in pre- and postmenopausal Vietnamese women with 
immunohistochemistry and silver in situ hybridization in operable breast cancers and 
compare the HER2 status in a series of Swedish patients (Study II). 
 3. To analyze cell proliferation as determined by Ki67 staining in breast cancers from 
Vietnam. The results were correlated with predictive and prognostic factors in breast 
cancers and compared with a series of Swedish breast cancer patients (Study III). 
 4. To examine the correlation between prognostic factors, treatment and survival in 
Vietnamese women with breast cancers treated at the National Cancer Hospital, Hanoi, 
Vietnam (Study IV). 
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4 PATIENTS AND METHODS 
 
4.1 PATIENTS AND SAMPLES 
In the National Cancer Hospital, Hanoi, Vietnam there is at present no computerized 
patients file or records. All patients in this study were registered with medical records at 
the breast cancer unit which takes care of treatment and follow-up. Therefore, a total of 
338 breast cancer paraffin blocks randomly selected from thousands of breast cancer 
samples which were stored disorderliness in the tumor bank at the department of 
clinical pathology. At first, blocks were picked out randomly and checked the tumor 
tissue in them and tumors equal to or above 0.5 cm in dimension were chosen for 
detailed study. Name of the patients, pathology report and medical record were 
identified then checked for proper clinical information such as age at diagnosis, 
menopausal status, clinical stage, tumor size and axillary lymph node status, 
histological subtypes (World Health Organization criteria) and tumor grade (Scarf-
Bloom-Richardson). Patients with neoadjuvant chemotherapy or/and inflammatory 
cancer or incomplete medical record were excluded. Finally, we contacted each patient 
via telephone for informed crosscut and to allow follow-up. After review, invasive 
carcinoma was selected for staining for the biomarkers. Two hundred and fifty six 
patients were eligible and enrolled in the study. Other cases were out of the scope of the 
current study because they were not adequate with our requisition. Moreover, the 
required sample size for the Vietnamese series was calculated to be two hundred and 
forty four. All clinicopathologic variables of these patients were stored in SPSS 
software as a questionnaire profile.  
 
4.1.1 Study I 
The hormone receptor levels for estrogen and progesterone were analyzed using 
immunohistochemistry in a series of 249 Vietnamese women with operable primary 
breast cancer treated the years 2002-2004 at the National Cancer Hospital, Hanoi, 
Vietnam since seven cases of immunostaining failed for technical reasons. The results 
obtained from the Vietnamese samples were compared to those obtained from 1,257 
Swedish breast cancers patients treated in the Stockholm region between the years 2002 
and 2003. The tumor receptor content in the Swedish series was analyzed by the 
enzyme immunoassay. We primarily compared the frequencies of hormone receptor 
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positivity in the two series and correlated the receptor status to clinical and pathological 
parameters.  
 
4.1.2 Study II 
The rates of HER2 protein overexpression and gene amplification were analyzed in the 
same series of operable primary breast cancer tissues as analyzed previously for 
hormone receptor content. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3: Steps to assess HER2 gene status in the two sample series 
 
 
A total of 242 patients were included and seven slides, as mentioned above, were not 
available for technique reasons. Moreover, the rate of protein overexpression by 
immunohistochemistry was compared with that of gene amplification as assessed by 
SISH staining. The rates of gene amplification in Vietnamese breast cancer materials 
were compared to those found in a series of 2,225 Swedish patients operated between 
the years 2007 and 2008 for invasive breast cancer in the Stockholm Region, Sweden. 
The rate of HER2 gene amplification was also assessed in correlation with 
clinicopathologic parameters for the Vietnamese patients. 
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4.1.3 Study III 
Of the invasive primary breast cancers in Vietnamese patients operated on during the 
years 2002-2003, as mentioned above, 237 tumors were analyzed for cell proliferation 
by staining for the anti-Ki67 antigen. Twelve cases were excluded because of illegible 
count.  In this study, all tumor tissues were sectioned to stain Hematoxylin-Eosin for 
classification of grade according to Elston-Ellis criteria.  Results were compared to 237 
age-matched Swedish women with breast carcinomas from the Department of 
Pathology of the Karolinska University Hospital, Solna who were operated upon in the 
period 2007 and 2008. These samples were also analyzed by staining for the Ki67 
antigen. The rate of cell proliferation in the two populations were compared and 
correlated to parameters such as patient age, clinical stage, tumor size, and the numbers 
of metastatic axillary lymph nodes.  
 
4.1.4 Study IV 
This study investigated the clinical outcome of the 248 Vietnamese patients described 
in the previous three studies. The patients were treated with either modified radical 
mastectomy or conservative surgery and axillary node sampling with a median of 10 
nodes (range 6-35). Classification of histological type was done according to WHO 
criteria. Tumor grade was assessed by the Scarff-Bloom-Richardson (SBR) as well as 
Elston-Ellis grading [51]. Informed consent was obtained from all patients before 
treatment. Patients operated on with modified radical mastectomy were treated with 
adjuvant radiotherapy for tumor ≥3 cm at a dose of 50 Gy to the chest wall and 50 Gy 
to the axillary area if node positive. Patients operated with breast conservative 
mastectomy were given 50 Gy to the entire breast and a boost to 60-65 Gy to the 
tumor bed. Patients with lymph node metastasis received adjuvant chemotherapy with 
anthracycline or taxane regimens. Of 123 premenopausal patients with hormone 
receptor-positive tumors, 104 (84.5%) received endocrine therapy including 74 
patients who were castrated with radiotherapy at a dose of 15 Gy. A total of 11 
patients entered menopause after chemotherapy and 19 patients were treated with 
tamoxifen. Postmenopausal women with hormone receptor-positive tumors were 
treated with tamoxifen at a dose of 20 mg oral daily for at least 2 years but often for 5 
years. In the first years, all patients normally were followed up with physical 
examination, blood tests for CA15.3 levels, chest x-rays and abdominal ultrasound 
examinations. Patients with symptoms suggesting metastasis were examined with CT/ 
MRI scans or bone scans. The majority of the patients were continuously followed up 
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by examination at the National Cancer Hospital, Hanoi but some patients living 
outside of the city were contacted by telephone. The last day of follow-up was July 
31, 2011, with a 99-month median follow-up (range 4-108 months). Patients who 
were alive after the last day of follow-up were censored.  
 
4.2 TISSUE MARKER ASSESSMENT  
Tissue handling for Vietnamese women with breast cancer in the Vietnam National 
Cancer Hospital was as follow. Five 4 µm-thick sections of each tissue paraffin block 
were produced. The tumor sections were stored at 2-8ºC before immunohistochemical 
staining. Positive and negative slide controls were included with every staining set.  
All of slides from Vietnam were stained at the Cancer Centre Karolinska (CCK), 
Karolinska Institute, Stockholm using the Ventana HX automatic system BenchMark 
(Ventana Medical Systems, SA, Illkirch Cedex, France), with the antibodies anti-ER 
(clone SP1) and anti-PR (clone 1E2). ER and PgR were defined as positive if 10% or 
more of the cell nuclei were stained. Enzyme immunoassay (EIA) utilizing the EIA 
monoclonal kits (ER-EIA and PgR-EIA, Abbott Laboratories, Abbot Park, IL, USA) 
was used for assessing hormone receptor status in Swedish samples and a cut-off point 
was positive at 0.10 fmol/µg DNA (Study I).  
In Study II, Vietnamese tumor samples were stained using an anti-HER2 antibody 
(clone 4B5) for detecting protein expression. Tumors with 2(+) and 3(+) protein 
expression were stained with SISH (silver in situ hybridization). A ratio of HER2 gene 
copies/chromosome17 above 2.2 was considered as amplified. Determination of HER2 
protein expression for Vietnamese and Swedish breast cancer series were applied as 
recommended [155]. In the series of samples from Swedish women, FISH 
(Fluorescence in situ hybridization) analysis was carried out as a part of histological 
routine using PatVision, the cut-off level being set at ≥2.0 as positive [79].  
The rate of tumor cell proliferation was measured by Ki67 immunohistochemistry 
staining by rabbit monoclonal antibody clone 30-9 with an automated machine of the 
Ventana Medical System. The tissue sections from the Swedish patients were stained 
using the automated Bond Max system. The antibody with Ki67 used in the Swedish 
series was the clone M7240 from the Dako Company. All of slides from both series 
were counted independently by two investigators under a light microscope. Four 
hundred cancer cells in each slide were evaluated in area with intermediate frequency 
of stained cells. The Ki67 index was measured as percent stained cells of total cancer 
cells (Study III). On the basis of biomarker profiles, the breast cancers in the study 
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population were also grouped into four phenotypic subtypes: luminal A [ER(+) or/and 
PgR(+) and HER2(-)], luminal B [ER(+) or/and PgR(+) and HER2(+)], HER2 enriched 
tumors [ER(-), PgR(-) and HER2 (+)] and triple negative [ER(-), PgR(-) and HER2(-)] 
(study III,IV). 
 
4.3 STATISTICAL ANALYSIS 
SPSS statistical program (version 15.0 for paper I/II and version 19.0 for paper III/IV, 
IBM. Chicago, IL, USA) was used to analyze the data. The Mann-Whitney test was 
used to compare the different categorical variables such as age at diagnosis, clinical 
stage, number of lymph nodes and tumor size between two populations (Study I). The 
odds ratio (OR) with 95% confidence interval (95% CI) and the Pearson's chi-square 
test (or Fisher's exact test when appropriate) used in relation with the fraction was 
calculated to measure the correlation or difference between variables of the two groups 
(all four studies). Kappa statistic was analyzed (Study II) for agreement between two 
procedures [156]. T-test was used for comparing the means with 95% CI, Wilcoxon 
rank-sum test for the median (Study III). Disease-free survival (DFS) was defined as an 
interval from the date of operation to the date of first detection of metastasis or 
contralateral breast cancer. Breast cancer specific survival (BCSS) was calculated from 
the date of operation to the date of death caused by cancer. Overall survival (OS) was 
defined as the date of operation to date of death of any cause or the last day of follow-
up. The survival rates were estimated by using Kaplan-Meier method. Log-rank test 
was used to compare DFS and OS between two groups for each parameter. Univariate 
and multivariate cox regression were used to determine the relationship between breast 
cancer deaths and prognostic and treatment factors (Study IV). All tests were two-sided 
and p≤0.05 value was used as the significant level in all four studies. 
 
4.4 ETHICAL ASPECTS 
All four studies were approved by the Hanoi Medical University Review Board 
(HMURB) No 38/HMURB and No 95/HMURB (extension), Ministry of Health (Vietnam) 
and ethical permits: Dnr 03-630/2003-12-01, Dnr 2007/1366-32 and 2011/2033-32 
from the Karolinska Institutet (Sweden). Vietnamese patients treated were voluntary to 
come back to the National Cancer Hospital for check-ups and to be interviewed via 
telephone about treatment aspects as well as symptoms. If a patient could not be 
contacted, the family members were interviewed to clarify the reasons for this failure. 
All collected information was handled anonymously.   
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5 RESULTS 
 
5.1 PROGNOSTIC CLINICOPATHOLOGIC CHARACTERISTICS  
In the current study, Vietnamese patients were younger than their Swedish counterparts 
at diagnosis (p<0.001). As seen in Table 4, sixty four percent of the Vietnamese 
patients were premenopausal while the corresponding figure was 25% for Swedish 
patients (Paper I) and 28% (Paper II).  
 
Table 4: Patients and tumor characteristics 
Variable Vietnamese 
(n=249) 
n  (%) 
Swedish 
(n=1,257) 
n (%) 
Age (years)   
Mean (SD) 47.5 (9.1) 60.7 (13.3) 
Menopausal status   
Premenopause 159 (64) 310 (25) 
Postmenpause 85 (34) 864 (69) 
unknown 5 (2) 83 (6) 
Tumor size (mm)   
Mean (±SD) 38.7 (±16.3) 23.7 (±14.9) 
Missing data 0 (0) 16 (1) 
Histologic type   
Ductal carcinoma 217 (86) 867 (69) 
Others 32 (14) 390 (31) 
DIS component 17 (7) 21 (2) 
Axillary node dissection   
Mean (±SD) 11 (±3.3) 9.4 (±5.2) 
Missing data 0 (0) 55 (4) 
Lymph node involvement   
Negative 141 (57) 692 (55) 
Positive 108 (43) 508 (40) 
Missing data 0 (0) 57 (5) 
Clinical stage   
I 26 (11) 655 (52) 
II 175 (70) 553 (44) 
III 48 (19) 49 (4) 
 
 
The mean tumor size from Vietnamese patients, as given in the histopathologic reports, 
was 38.7 mm compared with 23.7 mm for the Swedish patients (Study I). A similar 
distribution was also seen in Study III. The mean number of removed axillary lymph 
nodes was 11.0 for the Vietnamese patients, whereas 12% of Swedish patients 
underwent sentinel lymph node biopsy with maximum three lymph nodes recorded. If 
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these patients were excluded from calculations of the mean number excised lymph 
nodes which was 10.4 (SD=4.8) for Swedish patients. The percentage of patients with 
metastatic lymph nodes was similar in both groups; 43.4% for the Vietnamese vs. 
40.4% for the Swedish patients. Vietnamese patients had later Stages at treatment 
compared with Swedish patients. For Vietnamese women, clinical Stages I and II were 
reported in 10% and 70% of the population studied, respectively. The corresponding 
figure for the Swedish patients was 52% and 44%, respectively, p<0.001 (Table 4).  
 
5.2 HORMONE RECEPTORS 
The frequency of ER(+) tumors in Vietnamese patients (i.e. 61.8%) was lower than that 
for Swedish patients (OR, 95% CI, 0.58-1.02) (Table 5). This difference did not, 
however, reach statistical significance (p=0.060). Tumors with ER(+) were found in 
67.8% (Paper I) and 81.4% (Paper III) of the Swedish series. Even when it was used a 
cut-off point at 1% as positive, only one more Vietnamese patient was found to be 
classified as receptor positive. The ER(+) rate in Vietnamese patients increased from 
61.8% to 62.2%, which is still lower than that found for Swedish patients (data not 
shown). 
 
Table 5: Comparison of hormone receptor status between Vietnamese and Swedish 
patients with respect to menopausal status 
    ER    PgR     
    Vietnamese 
 n  
(%) 
Swedish  
n  
(%) 
P 
value 
OR* 
(95%  
CI) 
Vietnamese 
 n  
(%) 
Swedish  
n  
(%) 
P  
value 
OR* 
(95%  
CI) 
All patients (+) 151  
(61.8) 
800  
(67.8) 
0.060 0.76 113 
 (46.4) 
793 
(67.6) 
<0.001 0.41 
  (-) 93  
(38.2) 
374 
 (32.2) 
  (0.58-
1.02) 
131 
 (53.6) 
381 
(32.4) 
  (0.31-
0.55) 
Premenopause (+) 113  
(71.1) 
181 
 (58.4) 
0.007 1.75 92  
(57.8) 
226 
(72.9) 
0.001 0.51 
  (-) 46 
 (28.9) 
129 
 (41.6) 
  (1.16-
2.64) 
67  
(42.2) 
84 
 (26.1) 
  (0.34-
0.76) 
Postmenopause (+) 38  
(44.7) 
619 
 (71.6) 
<0.001 0.32 21  
(24.7) 
567 
(65.6) 
<0.001 0.17 
  (-) 47  
(55.3) 
245 
 (28.4) 
  (0.20-
0.50) 
64  
(75.3) 
297 
(34.4) 
  (0.10-
0.29) 
 
The ER(+) tumors were found in 71.1% of the premenopausal Vietnamese patients as 
compared to 58.4% of Swedish patients (Table 5). This difference in ER content 
between premenopausal Vietnamese and Swedish patients was statistically significant 
(p=0.007). In contrast, 44.7% of postmenopausal Vietnamese patients had ER(+) 
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tumors, which were much lower than the 71.6% observed for postmenopausal Swedish 
patients (p<0.001). The frequency of ER positivity was then calculated for clinical 
Stages I-II-III, for which the rates were observed as 70.5%, 66.7%, 44.9% for Swedish 
patients and 57.7%, 62.0%, 58.3% for Vietnamese patients, respectively. Thus, it 
appears that the rate of ER(+) tumors decreased with advanced stage in Swedish patients 
but not in Vietnamese patients. PgR(+) tumors were observed in 46.4% of Vietnamese 
and 67.6% of Swedish patients (OR, 99% CI 0.31-0.55) (Paper I) and 65.7% (Paper 
III). Even when 1% was used as a cut-off point for Vietnamese tumors, there were 7 
cases with expression at 5%. The PgR(+) rate increased for 2.8% (46.4% to 49.2%), 
which still was significantly lower than that (67.6%) for counterpart Swedish tumors, 
p<0.001 (data not shown).  
 
 
Fig. 4: The trends of ER and PgR positivity in relation to age of patients 
 
 
The frequency of ER positivity and PgR positivity in different age groups is presented in 
Fig. 4. The frequency of ER(+) was 76.3% for Vietnamese patients younger than 41 
years of age (Fig. 4). This frequency then gradually decreased with increasing age and 
was 35.0% for patients older than 60 years. For Swedish patients, an opposite pattern 
was observed and patients younger than 41 years were ER(+) in 43.3%. In the oldest 
age group, >60 years, the rate of ER(+) tumors increased to 73.9%.  
No significant difference in PgR positivity was found between Vietnamese and 
Swedish patients who were ≤40 years. However for patients >40 years, the PgR 
positivity of Vietnamese patients was much lower than that found for Swedish 
patients. The maximal difference was observed among patients over 60 years. In this 
age group, the Vietnamese and Swedish patients were PgR(+) in 35.0% and 65.5% of 
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cases, respectively. Our findings also show that the rates of PgR(+) tumors in 
Vietnamese patients were significantly lower than those for both counterpart pre- and 
postmenopausal Swedish patients.  
 
5.3 HER2 STATUS 
The information about the HER2 status in Vietnamese breast cancer patients is still 
limited. Immunohistochemistry (IHC) was used to analyze the HER2 protein 
expressed and it was found in 38.9% of the tumors with strong expression (3+). An 
intermediate level (2+) of the protein was found in 11.5% while 49.6% showed no or 
low (0/1+) levels. 
 
Table 6: Association of HER2 gene amplification with clinicopathologic variables in 
Vietnamese breast cancer patients 
 SISH OR (P value) 
Parameters  Negative 
n (%) 
Positive 
n (%) 
 
Age (yrs.) ≤50 97 (64.7) 53 (35.3) 2.1 (0.006) 
 >50 41 (46.6) 47 (53.4)  
Menopause Pre 98 (64) 55 (36) 2.2 (0.005) 
 Post 37 (45) 45 (55)  
Tumor stage ≤T1 21 (54.9) 17 (45.1) 0.93 (0.84) 
 >T1 110 (57) 83 (43)  
Histo- 
Pathology 
Ductal 
carcinoma 
120 (56.1) 94 (43.9) 2.3 (0.07) 
Others 18 (75) 6 (25)  
Tumor grade I, II 97 (53.6) 84 (46.4) 0.68 (0.36) 
 III 17 (63) 10 (37)  
Lymph node (+) 59 (57.3) 44 (42.7) 1.0 (0.85) 
 (-) 79 (58.5) 56 (41.5)  
ER status ER(-) 38 (43.2) 50 (56.8) 2.6 (0.0004) 
 ER(+) 100 (66.7) 50 (33.7)  
PR status PgR(-) 60 (47.2) 67 (52.8) 2.6 (0.0004) 
 PgR(+) 77 (70) 33 (30)  
 
 
The unexpectedly high frequency of tumors with protein overexpression motivated a 
further study using silver in situ hybridization (SISH) with which to analyze HER2 
gene amplification. An excellent correlation was found between protein 
overexpression and gene amplification (paper 2). HER2 gene amplification was found 
in 40.9% of the tumors and the concordance between the two techniques was 87%. An 
investigation was then undertaken to examine the correlation between HER2 gene 
   35 
status and other prognostic factors (Table 6). It was clear that HER2 gene 
amplification was more frequent in old patients, ductal carcinoma, high grade tumors, 
hormone receptor-negative tumors, but no difference was observed in various disease 
Stages in Vietnamese patients. 
As can be seen from Table 7, HER2 gene amplification in Swedish patients was 
observed in 13% of patients as analyzed by FISH. This result was then confirmed in 
study III. With age-matched patients, HER2(+) was found in 16% of Swedish patients 
(which was much lower than that of Vietnamese patients). In the counterpart Swedish 
series from Study II, premenopausal patients had frequency of HER2 gene 
amplification compared with postmenopausal patients of 16% vs.12%. 
 
 
Table 7: HER2 gene amplification in breast cancer samples taken from Vietnamese and 
Swedish women (%) 
 Vietnamese 
(n=242) 
Swedish 
(n=2,225) 
P value 
All patients 41 13 <0.001 
Premenopausal 36 16 <0.001 
Postmenopausal 55 12 <0.001 
ER positive 33 9 <0.001 
ER negative 57 31 <0.001 
 
 
5.4 CELL PROLIFERATION 
The rate of cell proliferation was analyzed in the same series of Vietnamese breast 
cancer tissues as used for analysis of hormone receptors and HER2, using 
immunohistochemistry with monoclonal antibody against Ki67 antigen. The number of 
Vietnamese samples with MIB-1 antibody was tested. Concordance between the two 
different antibodies used in the Vietnamese and Swedish counterpart series of tissue 
samples was high as tested in a limited series of tumors (data not shown). 
The rate of proliferation varied between 3% and 90% (Fig. 5). From this Figure, it can 
be seen that a majority of the tumors had a proliferation in the interval between 10% 
and 45%, with a median of 24%. In an age-matched counterpart series of Swedish 
patients, the cell proliferation varied between 1% and 95%, with a majority in the range 
4-50%.  
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Fig. 5a:  
Ki67 index distribution in 
Vietnamese patients, median: 24% 
Fig. 5b:  
Distribution of Ki67 index in 
Swedish patients, median: 20% 
 
Fig. 5: Vietnamese (A) and Swedish (B) patient group 
 
 
Based on the findings of the hormone receptors and HER2 status studies described 
above, the tumors in both series were classified into either luminal A, luminal B, 
triple negative or HER2 enriched. It can be seen that a high rate (>30%) of 
proliferation was observed in a minority of luminal A patients: 22.8% and 15.6%, for 
Vietnamese and Swedish patients, respectively. In contrast, the triple-negative and 
HER2-enriched subtypes were dominated by highly (>30%) proliferative tumors in 
both series of patients. 
 
Table 8: Comparison of Ki67 index and luminal status between breast cancer tumors in 
Vietnamese and Swedish patients (%) 
Variables  Frequency ≤15% 16-30% >30% 
Luminal A Vietnamese 44.1 30.7 46.5 22.8 
 Swedish 73.0 46.2 38.2 15.6 
Luminal B Vietnamese 22.3 31.4 37.2 31.4 
 Swedish 8.9 14.2 42.9 42.9 
Triple 
negative 
Vietnamese 14.4 18.2 39.4 42.4 
Swedish 10.5 12.0 12.0 76.0 
HER2 
enriched                   
Vietnamese 19.2 9.1 40.9 50.0 
Swedish 7.6 11.1 27.8 61.1 
 
 
5.5 SURVIVAL IN OPERABLE PRIMARY BREAST CANCER PATIENTS 
The DFS, OS and CSS rates of Vietnamese women with operable breast cancers were 
75.8%, 80.6% and 86.4% at 5 years, respectively; and 62.3%, 68.1%, 78.9% at 9 years. 
Lung was the most common site of metastasis in this population, followed by liver and 
bone (Paper IV). Also, those with favorable pathologic tumor factors including grade 
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I/II, negative axillary node and Stages I/II had significantly better survival (p=0.029, 
P<0.0001, and p<0.0001, respectively). 
 
Table 9: Results of univariate and multivariate analysis of crude survival rate 
Variable 
Univariate model Multivariable model 
HR (95% CI) P value HR (95% CI) P value 
Menopause     
Post Ref.  Ref.  
Pre 0.61 (0.38-0.95) 0.031 0.67 (0.41-1.08) 0.10 
Clinical stage     
I or II Ref.  Ref.  
III 2.55 (1.56-4.17) <0.0001
*
 2.45 (1.49-4.02) <0.0001
*
 
ER status     
(+) Ref.  Ref.  
(-) 1.23 (0.77-1.94) 0.39 0.76 (0.44-1.33) 0.34 
PgR status     
(+) Ref.  Ref.  
(-) 1.78 (1.11-2.85) 0.02
*
 1.77 (1.01-3.11) 0.045
*
 
HER2 gene 
status 
    
(-) Ref.  Ref.  
(+) 1.34 (0.85-2.11) 0.20 1.07 (0.66-1.73) 0.78 
 
 
The OS rates at 5 years and at 9 years were significantly higher in premenopausal 
patients as compared to postmenopausal ones: 84.5% vs. 72.3%; and 72.7% vs. 58.9%, 
respectively (p=0.03). Patients with ER(-) or PgR(-) tumors had worse OS after 5 years 
and after 9 years compared to those with receptor-positive tumors. In contrast, patients 
with HER2-amplified tumors also had lower survival as compared to those with non-
amplified tumors. Similarly, patients with ER(+) tumors showed a better survival than 
those with PgR negative ones. The ER and HER2 status of the tumors had little effect 
on the crude survival rate. 
The overall survival was different for pre- and postmenopausal patients in univariate as 
well as multivariate analysis (Table 9 and Fig. 6). Thus, premenopausal patients had a 
higher survival rate than postmenopausal patients. 
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Univariate analysis Mutivariate analysis (after adjusted stage, 
hormone receptors, HER2 status) 
Fig. 6: Overall survival of operable breast cancers by menopausal status 
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6 DISCUSSION 
 
6.1 HORMONE RECEPTORS 
Hormone receptors are biomarkers used in clinical routine since they are useful for 
selecting adjuvant therapy and as prognosticators. The previous findings in ethnical 
differences showed that tumors from Asian patients expressed low levels of hormone 
receptors compared to Caucasian patients. The ER(+), PgR(+)  rates in Vietnamese 
breast cancer patients living in the Greater San Francisco Bay Area (the USA) were 
55.5%, 48.1%, respectively [151]. ER/PgR(-) tumors from Vietnamese women were 
more frequent than those from non-Hispanic White patients in the USA [152]. 
Similarly, frequencies of hormone receptor positivity were low in breast cancers from 
Japanese women [157]. The PgR(+) rate in Asian patients was lower than for their 
Western counterparts [21]. It was found in the current study that both ER(+) and 
PgR(+) rates in Vietnamese were lower than those in Swedish women, 61.8% vs. 
67.8% and 46.4% vs. 67.6%, respectively. Tissue samples studied which had 1-9% of 
stained cells had low intensity. Although 1% was used as a cut-off, the hormone 
receptors from Vietnamese patients were still lower than those found in their Swedish 
counterpart. Patients with 1% stained cells probably are acceptable for endocrine 
therapy as this method has low toxicity: however those with tumors in which 1-9% 
cells were stained should be considered before treatment. Thus, tumors with low 
percentage expressed receptor normally showed a weak staining intensity [66]. That 
was the reason 10% was chosen 10% as cut-off point in the current studies for 
discriminate negative or positive assessment for tumor samples originating from 
Vietnamese patients. 
It is interesting that the frequency of ER(+) in premenopausal Vietnamese patients 
seemed significantly higher than that of premenopausal Swedish patients. Conversely, 
ER(+) rates of postmenopausal Vietnamese breast cancer patients were much lower 
than those of their counterpart postmenopausal Swedish patients. Notably Vietnamese 
women were diagnosed with breast cancer at a younger age and a majority of patients 
were diagnosed at or before menopause. This is in agreement with the previous 
findings which showed that Vietnamese patients and other Asian women at diagnosis 
of breast cancer were younger than non-Hispanic White patients [151, 152, 158]. In 
contrast, Swedish postmenopausal women had a higher incidence of ER(+) tumors. 
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From the data obtained in the current study, it is obvious that trend of ER(+) frequency 
decreased gradually for each 10-year group of Vietnamese women, from 76.3% to 
35.0%. But, interestingly, there was an opposite trend for Swedish women in whom the 
frequencies of ER(+) tumors were lower among patients 40 years or younger and high 
in patients above 61 years, increasing from 43.3% to 73.9%. Our findings are thus in 
general agreement with previous studies which showed a low frequency of ER(+) 
breast cancers in women from developing countries [159, 160]. The difference in 
ER(+) between the two counterpart series of samples used in the current studies varied 
in different age groups of patients, while the PgR(+) rates of Vietnamese patients were 
lower than those of Swedish women in all age groups. PgR(+) frequency in young 
Korean was also lower than that for Caucasian counterpart, 42.4% vs. 52.6% [153]. 
However, the trend of this marker by age has not been documented to date that needs 
further study for this issue. 
Risk factors such as age at first birth, postmenopausal obesity, and menopausal 
hormone therapy have been correlated to hormone receptor positivity in breast cancer 
[161]. The differences have also been partly explained by alcohol drinking, especially 
among those women who use postmenopausal hormone replacement [162]. One study 
from Sweden by Rosenberg et al showed that patients who had received long-term 
menopausal hormone therapy more often than not had hormone receptor-positive 
tumors [36]. Although the reason(s) for differences in hormone receptor status between 
races is unknown, true genetic differences are likely to be a major contributory factor. 
In addition, several factors such as difference in age at diagnosis and Stage present 
may be contributory. Lifestyle differences have also been suggested: women exposed 
to alcohol or contraceptive pills more often than not had ER(+) tumors [162, 163]. 
Reporting cut-off point is also one reason for producing different frequencies in 
hormone receptor assessments [56]. The low frequencies of hormone receptor-positive 
tumors indicate that few Vietnamese postmenopausal patients would likely benefit 
from endocrine therapy. In contrast, the high frequency of young patients with hormone 
receptor-positive tumors suggests that these patients could benefit from endocrine 
treatment. 
 
6.2 HER2 STATUS 
A previous clinical trial showed that HER2 protein overexpression was observed in 
26% from Vietnamese and Chinese premenopausal women in ER(+) tumors [85]. 
Another cohort study with 1,359 cases reported that 35.1% of breast cancers in 
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Vietnamese patients had HER2 protein overexpression which is considerably higher 
compared to results from Western countries [149]. The true frequency of HER2 gene 
amplification in Vietnamese breast cancer patients is, however, unclear because in situ 
hybridization had not been used prior to the current study. Using IHC to analyze HER2 
protein expression on Stage I-II-III breast cancer tumors, it was found that 38.9% of 
patients had overexpression and 11.5% of intermediate levels of protein expression and 
49.6% had no or low levels of expression.  Using SISH it was found that 40.9% of 
Vietnamese patients had tumors with HER2 gene amplification. Concordance between 
the IHC and SISH detections was 87%. These results are in agreement with reports 
from Asia that 31.5% of breast cancers  had HER2 protein overexpression in northern 
Malaysia [164]. A protein overexpression of HER2 was detected in 32% and gene 
amplification in 37.5% of cases reported in breast cancers from Thailand [41, 165]. 
Similarly, high rates (32-65%) of HER2 gene amplification were reported for large 
samples of Chinese breast cancer patients [166-168]. A most recent report from 
Southern Vietnam showed that HER2 gene amplification assessed by FISH was 36%  
[169]. In comparison with the counterpart series of tissues from breast cancer patients 
in Sweden, it was found that HER2 amplification in tumors from Vietnamese patients 
was significantly higher than that of their Swedish counterparts (40.9% vs. 15%), 
irrespective of other markers or menopausal status.  
Conflicting results concerning HER2 amplification and menopausal status both for 
Asian and Western women have been reported. With a comparison of five biomarkers 
and HER2 gene amplification between Caucasian and Korean patients younger than 45 
years, only HER2 gene amplification was significantly higher in Korean patients 
(47.5% vs. 15.8%), whereas other markers were not different [153]. HER2 gene status 
in this study was investigated in correlation with other prognostic markers. It was found 
that a high frequency of HER2 gene amplification was seen in postmenopausal patients. 
In a very recent study, overexpression of HER2 protein in two hundred patients in 
northern Malaysia was not significantly associated with age but that a high percentage 
(i.e.75%) of overexpression was noted in the age group 81-85 years [164].  Higher rates 
of HER2 overexpression in postmenopausal women were also seen in breast cancer 
patients in the south of Switzerland [170].  
Overexpression of HER2 protein was correlated with unfavorable factors such as 
lymph node positivity and large tumor size [40, 41, 74].  HER2 positivity was also 
signiﬁcantly associated with the Nottingham histological grade III (p<0.001), ER 
negativity (p<0.001), PR negativity (p<0.001) [53, 164]. The HER2 gene amplification 
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was more frequent in tumors with hormone receptor negativity, high grade, and high 
cell proliferation, but not related to age and tumor size [74, 171]. Despite these recent 
findings, the etiology of HER2 gene amplification today remains unclear. Differences 
in HER2 gene amplification may partly be explained by hormone replacement therapy, 
oral contraceptive and body mass index >27.3 kg/m
2
 all of which were associated with 
a lower frequency of HER2(+). Interestingly, patients who had been breastfeeding for 
≥12 months were more often than not found to have HER2(+) tumors [172].  
Trastuzumab is used for patients with HER2-amplified tumors but for Vietnamese 
patients the use of this agent is at present limited because of restrictive budgets. 
Nevertheless, our findings show that a high number of Vietnamese with breast cancer 
could have benefited from anthracycline-based chemotherapy and trastuzumab 
treatment.  
The luminal-A subtype is the most common phenotypic subgroup and was found in 
44.1% and 73% of Vietnamese and Swedish patients, respectively. Luminal-B, triple-
negative and HER2-enriched tumors were all more common in Vietnamese than in their 
Swedish patient counterparts.  
 
6.3 CELL PROLIFERATION MEASURED BY KI67 STAINING 
The rate of cell proliferation was analyzed in Vietnamese operable breast cancer 
patients who had a Ki67 index in the range of 3-90% (Fig. 5) with a majority above 
15%. Previous reports on Ki67 index in breast cancer showed discrepant results. The 
findings of the current study were similar to those obtained by Nishimura et al from 
Japanese patients who had a proliferation indices over 15% in 68% of the cases [101]. 
In contrast, a majority of Korean patients (78%) had a low cell proliferation index 
(under 14%) [173]. However, one study claimed that only 54% of breast cancer in 
Japanese women had a proliferation above 1% [174]. In the current study with age-
matched Vietnamese and Swedish patients, no significant statistical difference could be 
found in mean, median or range of cell proliferation between these two study 
populations. Findings for Swedish patients were consistent with those of other reports 
from Western patients in recent years [96, 97]. The variation in Ki67 index among 
various reports may reflect true variations but methodological differences such as those 
influenced by various methods of fixation, staining and evaluation: these could have 
had a major impact on results of Ki67. In addition, differences in the study cohorts and 
cut-off levels may contribute to the variations [175].  
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The Ki67 index is classified as low (≤15%) and high (>15%), it was found that the 
frequency of high Ki67 index tumors from Vietnamese patients was higher than those 
indices obtained from their Swedish counterparts: 75.9% vs. 62.9%, P=0.011, (data not 
shown). This is in agreement with a report that the Ki67 index was higher in tumors 
from African-American as compared to Caucasian patients living in the USA [176]. 
During the current study, the mean Ki67 indices were compared between two series 
according to various clinicopathologic parameters. The means of Ki67 indices of breast 
tumors in Swedish patients were higher than those of counterpart Vietnamese patients 
according to poor prognostic factor subsets, such as hormone receptor negativity and 
HER2 gene amplification. Contrastingly, in tumors with good prognostic factors, the 
mean values were higher in tumors present in Vietnamese patients. It was obvious that 
mean Ki67 indices in tumors with poor clinicopathological factors were higher than 
those with favorable factors in both series. These findings may partly support the notion 
that chemotherapy should be indicated for patients who have unfavorable factors 
(results and evidence presented in Paper III). 
Until recently, there has been no consensus on reliable cut-off point for low and high 
Ki67 indices. However, two recent reports from the St Gallen Conference addressed 
this issue. It has been suggested that breast carcinoma should be classified into three 
groups: low (≤15%), intermediate (16-30%) and high (>30%) rates of proliferation 
that aid selection of a type of adjuvant therapy [44]. In the present study, the Ki67 
levels which had been divided into three intervals were also associated with 
prognostic factors. It was found that Ki67 levels were significantly associated with 
factors such as histologic subtype, tumor grade, ER, PgR and HER2 gene 
amplification. This means that Ki67 level was not independent of both pathologic and 
biomarker characteristics, according to suggestions from other researchers [84, 101, 
171]. 
In this study, frequencies of Ki67 indices were compared according to biomarker 
subtype. The findings support previous reports that the good prognosis luminal A has 
few tumors with a high proliferation. In contrast, triple-negative and HER2-enriched 
tumors from Vietnamese and Swedish patients were more often than not highly 
proliferative (>30%). Furthermore, the rate of cell proliferation among the four 
subtypes showed less variation in the Vietnamese series as compared to tumors from 
Swedish patients. A comprehensive search of the literature showed that this is the first 
comparative report on the rate proliferation in the immunohistochemical subtypes in 
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tumors from Asian and Western patient populations. It will be of interest to study the 
prognostic value of this subtyping in Vietnamese patients, as well as of the 
proliferation rates, as a potential independent prognostic factor. Furthermore, the 
results of the current study provide a baseline cohort for comparative studies on 
breast cancers of other ethnicities and especially of Vietnamese who have migrated 
over varying periods of time to Western countries. 
 
6.4 BIOMARKER PHENOTYPES AND SURVIVAL  
Little is known about the clinical outcome of Vietnamese breast cancer patients. In the 
current study, the disease-free survival (DFS), breast cancer-specific survival (BCSS) 
and overall survival (OS) in the series of breast cancer patients which were 
characterized for clinicopathologic and biomarker profiles (Studies I-III). The 5-year 
overall survival in the present study was 80.6% for the series of Vietnamese patients, 
which was comparable to reports from Cote d’Or region of France (74%) and from the 
Eastern region of England (78%) [177, 178]. Also, the 5-year survival of young 
Vietnamese women treated in the Central Cancer Hospital in Hanoi (81%) is consist to 
that reported in the Eastern region of England [178], but was lower than the figure from 
a recent Wishart- study in England at 9 years after diagnosis. It is considered that the 
OS levels reported for Vietnamese breast cancer patients were comparable to the 
English patients since they had been given similar treatment. The guidelines for 
diagnosis and treatment of breast cancer have been improved resulting from a 
collaborative program between the National Cancer Hospital and the University of 
Wisconsin since 1993 [179]. National Cancer Hospital is the largest cancer center in 
Vietnam treated for patients from Northern and middle Vietnam; therefore most 
advanced treatment applied. A recent report from Malaysia and Singapore showed that 
the 5-year survival for Stages II and III was lower than that found in the current study, 
which may be explained by patient recruitment from different hospitals with various 
therapeutic approaches and variations in tumor prognostic factors [180]. Breast cancer 
survival has been shown to be different for pre- and postmenopausal patients [170]. In a 
very recent observation for survival of breast cancer patients in Sweden, risk of 
mortality in addition to traditional risk factors depends on the age of immigrant races 
[5]. One population-based study in Hong Kong showed that DFS of Chinese patients 
was higher than the finding of this study for Vietnamese patients (81.2% vs. 75.8%), 
but no difference was observed for breast cancer-specific survival (85.2% vs. 86.4%) 
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[181]. Breast cancer survival observed in the current study was comparable to that 
reported in other Asian and Western countries. 
As described above, Vietnamese postmenopausal patients had tumors that more often 
than not had poor prognostic factors. In univariate analysis, it was found that 
postmenopausal patients had lower survival (Fig. 6), but this difference was not 
significant in a parallel multivariate analysis (Table 9). It seems likely that the different 
survival in pre- and postmenopausal women was seen because of the various 
proportions of prognostic factors [46]. On the other hand, the breast cancer patients 
after diagnosis may also have died from causes other than breast cancer in the different 
age groups [39].  
In general, patients with favorable prognosticators experience better survival. Lymph 
node status was the strongest factor for prediction of survival [40]. This can probably 
be explained by the fact that lymph node status reflects disease extent [32]. Tumor 
grade was found to be an important factor in the current study. Risk of mortality was 
increased from low grade to high grade tumors (19%, 50.4%, respectively) after 9 
years. Patients with ER(+) had general a better survival as compared to those with ER(-
), but this difference was not statistically significant. This may, however, be partly 
explained by adjuvant chemotherapy given to patients with ER(-) tumors. Thus, 40.9% 
of patients with ER(-) tumors received chemotherapy as compared to 34% of those with 
ER(+) (data not shown). In contrast, PgR status was an independent significant factor 
for patient survival, according to both univariate and multivariate analyses. Although 
HER2 status in the current study did not relate statistically to survival, it seems that 
patients with HER2-amplified tumors have poor survival (Table 9). When combining 
data of the hormone receptor and HER2 statuses, so as to subdivide the tumors into four 
phenotypic subtypes, patients with luminal A had the best survival, whilst the worst 
survival was observed for patients with triple-negative tumors. These findings are 
consistent with previous reports based on random samples from either Asian or 
Western women with breast cancer [39, 41, 157, 178, 182]. Available data suggest that 
Asian patients more often than not have high grade, ER(-) tumors which contribute to a 
lower survival rate than is the case for Western patients. It should, however, be pointed 
out that the survival of patients suffering from breast cancer is not only dependent on 
clinicopathological features but also on the availability of treatment [178]. 
Most of the Asian countries are low- and middle-income countries where the late 
detection and available access to care, survival of women with breast cancer in Asia 
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is likely to be adversely affected in comparison with Western countries. In most 
Asian countries, improvement of breast health care remains a challenge that should be 
overcome with collaboration from multiple hospitals, both public and private. 
 
6.5 METHODOLOGICAL ASPECTS 
Today prognostic and predictive biomarkers play an important role in the management 
of breast cancer patients. A prerequisite for their application in clinical routine is that 
they can be reliably and reproducibly analyzed. The commonly analyzed biomarkers 
such as hormone receptors, HER2 status and cell proliferation have all been assessed by 
several different techniques. Some of these today are accepted as gold standards in 
clinical routine work. In the current study of such biomarkers in breast cancers from 
Vietnamese patients, the most recent and well-documented methods for their analysis 
were used. This approach allowed the current investigations to make reliable 
comparisons with series of breast cancers present in a population of Swedish patients. 
 
Hormone receptors: Immunohistochemistry was used for the analysis of the receptor 
content in sections from Vietnamese breast cancers. An automated platform 
reproducibly stained the slides which were assessed by counting 400 tumor cells in 
each sample. Ten percent stained nuclei was chosen as a cut-off point between 
receptor-negative and receptor-positive tumors. In a series of Swedish breast cancer 
patients operated on between 2002 and 2003, it was found that 342 cases had been 
stained with both IHC and EIA. However, these cases had been stained at different 
hospitals with various antibodies and different staining methods. At this time, hormone 
receptor analyses were also carried out in a reference laboratory which still used the 
EIA technique and participated in a nationwide quality control program [64]. This 
allowed a comparison of receptor positivity as defined by EIA technique in 342 cases. 
This resulted in a kappa value of 0.56. This relatively poor level of concordance was 
most likely caused by the use of various techniques for the IHC analysis. Therefore, it 
was decided to use the results from the EIA assessment, although the definition of 
receptor positivity was based on a biochemical measurement instead of IHC staining. In 
spite of these methodological differences, it was believed that a comparison between 
hormone receptor content in the two series in the end gave reliable results. 
 
HER2 analysis: In the Stockholm Region during 2007-2008, IHC and FISH were used 
to define the HER2 status of breast cancers. The tumors were stained with IHC and 
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tumors with 2+ and 3+ protein expressions were further analyzed for HER2 
amplification by FISH. A similar approach was used for testing HER2 amplification in 
the cases of counterpart Vietnamese breast cancers. In the first place IHC was used to 
identify tumors with protein overexpression (2+ and 3+). These tumors were then 
analyzed for gene amplification using SISH. SISH approach was chosen because the 
slides could be evaluated using light microscopy which also allowed for a morphologic 
control to be made. The reliability of SISH is high and a concordance of 96% with 
FISH data has previously been described [183-185]. In addition, SISH has been 
approved by the American Food and Drug Administration for analysis of HER2 gene 
amplification. It was therefore considered that the comparison between HER2 status in 
Vietnamese and Swedish breast cancer was valid for the purposes of the current 
investigations. 
 
Cell proliferation: Today the most accepted and used technique for analysis of growth 
rate in tumors is evaluation of IHC staining of Ki67. The technique is robust and 
reliable but it should be stressed that the evaluation can be controversial. This is 
because the staining intensity of samples can vary between the different growth phases 
and may therefore lead to an underestimation of the growth fraction. In the series of 
Vietnamese breast cancers applied in the current study, automated staining was used an 
anti-Ki67 (30-9) rabbit monoclonal antibody. Each sample was evaluated by counting 
400 tumor cells in an area of tissue sections showing intermediate proliferation. The 
counterpart tumor samples from Swedish patients were also stained in an automated 
platform using the MIB-1 antibody. The staining property was compared with the two 
antibodies used also in a series of Vietnamese breast cancers and was found to give a 
good correlation. The Swedish samples were also counted to standardize the 
evaluations since they had been originally scored by several pathologists that made the 
primary results less reproducible. It was therefore considered that the current 
comparison of this marker of breast cancer samples from counterpart materials of 
Vietnamese and Swedish was valid. 
 
Survival: As previously pointed out, clinical follow-up of Vietnamese breast cancers 
patients is hampered by lack of computerized patient files and frequent drop-out of 
patients, mostly caused by economy. All available patient records were read and 
relevant clinical information computerized. In patients with incomplete records, a 
telephone contact was made with either the patient or a relative to obtain relevant 
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information. Patients who had metastasis diagnosed and later died were registered as 
dead from disease. In none of these cases was the cause of death verified by autopsy 
since this is not performed by tradition in Vietnam. Findings of the current study 
indicate however that breast cancer survival of women treated at the National Cancer 
Hospital, Hanoi, Vietnam have a prognosis comparable to that of breast cancer patients 
in Western countries. 
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7 CONCLUSIONS AND PERSPECTIVES 
 
Both marked differences and similarities were found between operable breast cancer 
patients from Vietnam and Sweden. Vietnamese patients were younger at diagnosis 
and had more often advanced stages of the disease. The tumor biomarker profiles 
showed a higher frequency of ER(+) tumors in premenopausal- and lower frequency 
in postmenopausal patients. HER2-amplified tumors were more common in both 
among Vietnamese pre- and postmenopausal patients.  
The rate of cell proliferation in Vietnamese breast cancer patients showed a similar 
distribution to that of Swedish patients. Moreover, the breast cancer survival rate for 
Vietnamese patients was similar to that for Western patients.  
The first study for Vietnamese patients living in Northern and middle Vietnam also 
suggests that Vietnamese breast cancers have different tumor cell characteristics to 
those reported for Caucasian patients in general. The results provide a basis for 
further comparative studies with breast cancer patients of other ethnical background. 
Today there are no nationwide screening and treatment programs for breast cancer in 
Vietnam. In addition, biomarkers are only analysed in a few sufficiently equipped 
pathology laboratories. These are challenging matters for the future. Economical 
restraints are at present difficult to overcome and this will have an impact on the 
introduction of new more precise techniques for early detection of breast cancer as 
well as the introduction of new therapeutic agents which could be used for a more 
individualized therapy if all tumors could be analysed for the biomarkers described in 
this study.  
The contribution of BRCA mutations to breast cancer development seems low in 
Asian patients. Identification of other genetic factors and their correlation to treatment 
response is accordingly a most challenging field for future research. 
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